STATISTICS IN MEDICINE
Statist. Med. 2000; **19**: 3523–3526

AUTHOR INDEX

Abate, J. F., 99
Abrams, K. R., 3359
Abramson, I. S., 1421
Agresti, A., 1115, 1771
Akazawa, K., 1955
Akhtar-Danesh, N., 1889
Allen-Mersh, T. G., 3237
Altman, D. G., 453, 3275
Ambrosius, W. T., 1339
Andersen, P. K., 587
Anderson, S., 887
Appleton, D. R., 1889
Arends, L. R., 3497
Armitage, P., 3165
Armstrong, P. W., 2037
Arnold, A., 1411
Aryan, M., 1401
Ashby, D., 3291
Auranen, K., 281

Bainbridge, J., 3389
Baltzan, M., 1901
Barber, J. A., 3219
Barón, A. E., 1969
Bartfay, E., 373
Baur, M. P., 3337
Bebchuk, J. D., 405
Becker, N. G., 1165
Beckett, L. A., 681, 1469
Bedrick, E. J., 221
Begg, C. B., 1997
Beiser, A., 1495
Bell, B. S., 957
Bellocco, R., 297
Benach, J., 2409
Berg, J. D., 1433
Berger, V. W., 1303, 1319
Bernardinelli, L., 2493
Bernardo, M. V. P., 3023
Bernsen, R., 1849
Berridge, D. M., 3377
Besag, J., 2243
Best, N. G., 2493
Betensky, R. A., 405
Biggeri, A., 2217, 2539
Biggerstaff, B. J., 649
Binks, K., 849
Birch, J. B., 389
Bithell, J., 1141, 2203
Blackman, N. J.-M., 723
Blettner, M., 3345
Boehning, D., 2217
Böhning, D., 2333
Bolland, K., 2899
Bonetti, M., 2595
Borgdorff, M., 1849
Bouckaert, A., 239
Boyett, J. M., 205
Boyle, D., 2811
Brender, J. D., 1081
Brittenham, G. M., 83
Brock, D., 1577
Broemeling, L. D., 957
Brookmeyer, R., 1481
Broom, B. M., 1217
Brown, J., 3389
Brunner, D., 3345
Byers, S., 2243

Cai, J., 2963
Cardon, L. R., 369
Carlin, B. P., 2265, 2279
Carpenter, J., 1141
Carr, D. A., 2521
Carr, D. B., 2521
Castillo-Chavez, C., 827
Catellier, D. J., 1101
Chang, Y.-C., 1277
Chastang, C., 837
Chaturvedi, N., 861
Chau, N. P., 1207
Chen, C. W. S., 3095
Chen, J. J., 2089
Chen, M.-L., 2821
Chen, P.-L., 71
Chen, Y.-I., 353
Chevret, S., 837
Chinchilli, V. M., 2855
Chinn, S., 3127
Chong, M. Y., 743
Chow, S.-C., 1029, 2741
Christensen, R., 221
Christiansen, O. B., 2147
Clark, A., 2217
Clark, L. C., 1303
Cohen, A., 2699
Cole, D. E. C., 743
Cole, T. J., 3109
Cook, J. R., 2989
Cook, N. R., 2625
Cooke, G. E., 923
Corcorcan, C., 3037
Craddock, C., 3005
Cramer, L. D., 1997
Cressie, N., 2377
Cronin, K. A., 1729
Cronin-Stubbs, D., 1453
Cui, J., 1165
D'Agostino, R. B. Sr, 763, 1495
Dannegger, F., 475, 601
Davidov, O., 1983
Dean, C. B., 2421
Deguen, S., 1207
DeKosky, S. T., 1453
Delgado-Rodriguez, M., 1089
Diamond, M. R., 1295
Dickinson, H. O., 849
Dietz, E., 2333
Diggle, P., 849
Ding, L., 1363
Divino, F., 2217
Do, K.-A., 1217
Dominik, R., 71
Donner, A., 373
Doornbos, G., 2569
Dubray, B., 1237
Duffy, D. L., 1217
Duh, S.-H., 99
Dunson, D. B., 665
Dyba, T., 1741

Eberly, L. E., 2279
Eckhardt, L., 2933
Edland, S. D., 1441, 1617
Edwardes, M. D. deB., 715, 1901
Egea, J. M., 2641
Eijkemans, M. J. C., 141, 1059
Elliot, P., 2493
Elston, R. C., 369
Emir, B., 511
Emsley, C. L., 1523
Endrenyi, L., 2867
Engels, E. A., 1707
Esbjerg, S., 587
Escolano, S., 3465
Evans, D. A., 1453
Evans, S. J. W., 3199

Faraggi, D., 61
Faries, D. E., 2169
Fay, M. P., 335
Fayers, P. M., 2657
Feldman, U., 575
Feng, J., 2169
Feuer, E. J., 335, 1729
Fidler, V., 1849
Flynn, E. V., 3325
Forand, S. P., 2399
Formann, A. K., 1881
Foster, N. L., 1531
Friede, T., 901

Galasko, D. R., 1421
Gao, S., 1523, 1545, 1567, 2101
Garner, P., 3325
Gelb, D. J., 1393
Gelber, R. D., 2595
Gelfand, A. E., 1865
Gelman, A., 2309
Geskus, R. B., 1753
Gigli, A., 175
Gilbert, P. B., 3065
Gill, P. S., 975
Gillman, M. W., 2625
Girling, D. J., 2657
Giudici, P., 2579
Glassman, J. R., 113
Glasziou, P., 1295
Goldman, D. A., 1081
Goldman, J. M., 3005
Goldschmidt-Clermont, P. J., 923
Goldstein, H., 2469, 3417
Golmard, J.-L., 3465
Gombosi, E., 1531
Gómez, G., 2641
Gould, A. L., 2721
Gould, R. L., 1421
Graham, P., 937
Gray, S., 1481
Grobbee, D. E., 3497
Guggenmoos-Holzmann, I., 1783
Guihenneuc-Jouyaux, C., 45

Habbema, J. D. F., 141, 1059
Hahn, S., 3325
Hakulinen, T., 1741
Haley, V. B., 2399
Hall, C. B., 1555
Hall, K. S., 1523, 1645, 2101
Hamilton, D. C., 743
Hanley, J. A., 313, 715
Harrell, F. E. Jr, 1059
Hartel, G., 1295
Hartzel, J., 1115
Hauck, W. W., 887, 2821
Hauptmann, M., 2185
Hauschke, D., 2769
Hazes, M. H., 3433
He, Z., 2015
Heisterkamp, S. H., 2569
Henderson, R., 563
Hendrie, H. C., 1523, 1645, 2101
Hennekens, C. H., 2625
Hernández-Suárez, C. M., 827
Heyse, J. F., 2989
Higgs, R. E., 1697
Hilden, J., 431
Hill, E. G., 1363
Hilton, J. F., 989
Ho, H.-T., 1029
Hoes, A. W., 3497
Højbjerre, M., 2147
Holder, D. J., 2885
Horton, R., 3149
Horvath, S., 3337
Hsiao, C. K., 1915
Hsieh, Y.-H., 3095
Hsuan, F., 2879, 2885
Hu, F., 2067
Hughes, M. D., 3171
Hui, S. L., 1339, 1545, 1567, 2101
Hundborg, H. H., 2147
Hung, H. M. J., 2079
Hutton, J. L., 3325
Hyneck, M., 2811
Hyslop, T., 887, 2821, 2885
Hytönen, M., 1179

Ibrahim, J. G., 3023
Izmirlian, G., 1577

Jensen, K., 493
Johnson, W. O., 221
Jones, D. R., 3359
Jung, S.-H., 511

Kambour, E. L., 83
Kang, S.-H., 2089
Kastner, C., 3345
Kelly, C., 2919
Kelly, P. J., 13
Kieser, M., 901
Kim, H., 2015
Kim, H.-J., 335
Kimanani, E. K., 2775, 2797
Kinukawa, N., 1955
Kittner, S. J., 99
Klar, N., 373
Klein, J. P., 3005
Kleinman, M., 1651
Klinger, A., 601
Knorr-Held, L., 2539, 2555, 2579
Koch, G. G., 781, 1039
Korinek, A.-M., 3465
Koval, J. J., 723, 1685
Kreienbrock, L., 2185
Kryscio, R. J., 1463, 1607
Kuhnert, P., 1217
Kulkarni, P. M., 2975
Kulldorff, M., 2399

Lagazio, C., 2539
Langford, I. H., 2469
Lasserre, V., 45
Lau, J., 1707
Lauritzen, S. L., 2147
Lavigne, J., 2775
Lawmepol, A., 1931
Lawson, A. B., 2217, 2361, 2451
Le, N. D., 2437
Lee, K. L., 141
Lee, S.-M., 3095
Lee, Y. J., 1329
Leporrier, M., 837
Leroux, B. G., 2321
Lertprapai, S., 1931
Lesaffre, E., 2217
Leyland, A. H., 2469
Li, X., 83
Lim, L. L.-Y., 13
Lin, C., 2309
Lin, H., 1303
Lin, L. I.-K., 255
Lindsey, J. K., 35, 801
Lipton, R. B., 1555
Littell, R. C., 1793
Little, R. J. A., 1531
Liu, A., 205
Liu, H., 2409
Liu, X., 1593
Llorca, J., 1089
Louis, T. A., 2295
Lubin, J. H., 2185
Lubsen, J., 3497
Lui, K.-J., 2919, 2933
Lukaski, H. C., 83
Luz Calle, M., 2641

McCulloch, C. E., 1303
McElvenny, D., 3389
McLachlan, G. J., 83
McLaren, C. E., 83
McLaren, G. D., 83
MacNab, Y. C., 2421
Maestri, R., 3087
Magder, L. S., 99
Mallet, A., 3465
March, J., 697
Marchi, M., 2539
Mariotto, A. B., 161
Marrett, L. D., 2437
Marschner, I. C., 297
Marshall, G., 1969
Martin, N. G., 1217
Martus, P., 525
Martuzzi, M., 2539
Mason, S., 3389
Mauger, D. T., 2855
Mayer, J. A., 2933
Mazumdar, M., 113
Mazza, A., 3087
Mehrotra, D. V., 811
Mehrotra, K. G., 2975
Mehta, C., 3037
Mendiondo, M. S., 1607
Michalek, J. E., 2975
Midthune, D. N., 335
Miller, J. P., 1463
Millikan, R. E., 1011
Milliken, J. K., 1617
Moeschberger, M. L., 923
Mohs, R. C., 1401

Morris, J. C., 1453
Morton-Jones, T., 849
Mosseri, V., 1237
Moyé, L. A., 767, 795
Muga, R., 2641
Müller, H.-H., 493
Muller, K. E., 1101
Mungas, D., 1631
Munk, A., 2843
Musick, B. S., 1645

Nagelkerke, N. J. D., 1849, 2569
Nakamura, T., 1955
Natarajan, R., 1793
Negassa, A., 715
Nixon, J., 3389
Nose, Y., 1955
Nottingham, Q. J., 389
Nurminen, M., 1179

Ocepek-Welikson, K., 1651
Olkin, I., 1707
Olley, B., 1645
Omar, R. Z., 2675, 3417
O'Neill, R. T., 785
Opasich, C., 3087
Oyediran, A. B. O. O., 1645

Pan, W., 1, 2611
Park, E., 1329
Parker, L., 849
Parker, R. A., 2131
Parmar, M. K. B., 2657
Pascutto, C., 2493
Patnaik, R., 2821
Patterson, S. D., 2811
Pederson, L. L., 1685
Pendergast, J., 1793
Penttinen, A., 2345
Pinna, G. D., 3087
Platt, R. W., 313, 323
Potvin, D., 2775
Prevost, T. C., 3359
Price, P. N., 2309
Prince, H., 563

Qian, W., 2657
Qiu, P., 923

Railkar, R., 811
Ranta, J., 2345
Rasbach, J., 2469
Rasser, G., 2579
Reed, B. R., 1631
Reidpath, D. D., 1295
Reiser, B., 2115
Ribaudo, H. J., 3237
Richardson, S., 45, 2493
Roberts, R. J., 1645
Robinson, N. J., 3193
Robson, D. L., 2437
Rockhold, F. W., 3211
Rosai, J., 1997
Rosenberg, P., 2185
Rosenberger, W. F., 2067
Rosner, B. A., 2625
Royston, P., 453, 1191, 1831, 2053, 2943
Ruberg, S. J., 913

Sackrowitz, H. B., 2699
Sackrowitz, M., 2699
Sala, E., 1179
Salmon, D. P., 1421
Sambrrok, R. J., 2657
Sanarico,M., 3087
Sano, M., 1433
Santos, D. M. Dos, 3377
Sato, T., 2689
Sauerbrei, W., 441
Schäfer, H., 493
Schelhaas, D. D., 3433
Schenker, N., 1237
Schinazi, R. B., 2185, 2195
Schlattmann, P., 2217, 2333
Schmeidler, J., 1401
Schmid, C. H., 1707
Schmitt, F. A., 1463, 1607
Schmoor, C., 441
Schuirmann, D. J., 2821
Schumacher, M., 441, 541
Schwarzer, G., 541
Semenciw, R. M., 2437
Senchaudhuri, P., 3037
Senn, S., 861
Seshadri, S., 1495
Shao, J., 1029, 2741
Sharp, S. J., 3251
Shen, W., 2295
Shen, Y., 2963
Shoukri, M. M., 373
Sirichaisinthop, J., 1931
Slate, E. H., 617, 1303
Sliwinski, M., 1555
Sloan, M. A., 99
Smith, A. F. M., 3291
Smith, T. E., 2479
Sørensen, T. I. A., 587
Sorribas, A., 697
Staines, A., 2493
Stallard, N., 3051
Steiner, M. J., 71
Steinijans, V. W., 2769
Stephens, R. J., 2657
Stern, H. S., 2377
Steudel, I., 575
Stevens, L., 861
Stewart, W. F., 1555
Stewart, W. H., 913
Steyerberg, E. W., 141, 1059
Stijnen, T., 3497
Sullivan, L. M., 1495
Sun, D., 2015
Sung, H.-G., 1011
Svensson, E., 3483
Szydlo, R. M., 3005

Taback, N., 2867
Talbot, T. O., 2399
Tamura, R. N., 2169
Tancredi, D. J., 681
Tangen, C. M., 1039
Tangenti, A., 3087
Tango, T., 191
Taylor, J. M. G., 1237
Taylor, J. O., 2625
Teboe, C., 1531
Teresi, J. A., 1593, 1651
Terrin, N., 1707
Thal, L., 1433
Thall, P. F., 1011
Thomas, G., 1207
Thomas, R., 2479
Thomas, R. G., 1433
Thompson, S. G., 2675, 3219, 3237, 3251, 3417
Tiensuwan, M., 1931
Todd, S., 3051
Todorov, A. A., 1217
Tothfalusi, L., 2867
Treloar, S. A., 1217
Tripathi, R. C., 2975
Tsutakawa, R. K., 2015
Turnbull, B. W., 617, 1303
Turner, D., 2437
Turner, R. M., 3417
Tyas, S. L., 1685
Tzeng, J.-Y., 1915

Ulm, K., 601

Vach, W., 541
Vaida, F., 3309
van Belle, G., 1411
van der Bas, J. M., 3433
Van der Tweel, I., 3449
van Duinen, S. G., 3433
van Houwelingen, H. C., 1783, 3401
van Houwelingen, J. C., 141
Van Noord, P. A. H., 3449
Venkatraman, E. S., 1997
Verdecchia, A., 161, 175
Viel, J.-F., 2217
Voit, E. O., 697
Voskuyl, A. E., 3433

Wakefield, J. C., 2493
Waller, L. A., 1363
Wallin, J. F., 2521
Walter, S. D., 2437
Wang, B., 2741
Wang, C.-H., 1915
Wang, F., 1865
Waternaux, C., 1593
Weinberg, C. R., 665

Wellek, S., 2755
Wellmann, J., 2185
Wesson Ashford, J., 1607
White, L., 1577
Whitehead, J. R., 2899
Wieand, S., 511
Williams, F. L. R., 2451
Williams Pickle, L., 2251
Williams, R., 2821
Williamson, P. R., 3325
Windeler, J., 425
Winget, M., 2409
Witte, J. S., 369
Wolf, P. A., 1495
Wong, E., 71
Wong, W. K., 639
Wright, E. M., 2943

Xiong, X., 205
Xu, R., 3309

Yang, H., 313
Yang, M., 3417
Yasui, Y., 2409
Ying, Z., 511

Zariffa, N. M.-D., 2811
Zelen, M., 1983
Zheng, B., 1265, 1771
Zhou, X.-H., 1697
Zhu, L., 2265
Zhu, W., 639
Zhuang, D., 1237
Ziegler, A., 3345
Zwinderman, A. H., 3433

STATISTICS IN MEDICINE
Statist. Med. 2000; **19**, 3527–3552

SUBJECT INDEX*

Notes: Single page numbers refer to individual papers.

absolute risk reduction, 3275
accelerated failure time (AFT), 221
  prognostic survival model, 3401
acoustic rhinometry, reproducibility modelling, 1179
activities of daily living (ADL), Alzheimer's disease, 1393, 1401, 1433
acute myelogenous leukaemia, bootstrap confidence intervals, 1141
adaptation method, prognostic models, 141
adaptive designs, time trends, 2067
additive hazards model, HIV incidence rate estimation, 1165
additive isotonic regression models, 849
adjusted *p*-value, unbalanced factorial design clinical trials, 2079
age-at-diagnosis, cystic fibrosis, 743
age-related trends, S-distributions, 697
age-specific incidence
  Alzheimer's disease, 1481
  back-calculation, 281
age-specific models, incidence prediction, 1741
age-specific reference intervals, goodness-of-fit, 2943
age-standardized rates (ASIRs), Canadian Cancer Incidence Atlas, 2437
aggregate criterion
  bioequivalence, 2769, 2821, 2879, 2885
  of population bioequivalence, 2755
Agresti's α, 1901
AIDS
  HIV incidence rates estimation, 1165
  incubation time uncertainty, 175
  mortality data, epidemics reconstruction, 161
  multiregion contact systems, 2479
  prognosis, oral candidiasis episodes, 989
  surveillance data, back-calculation, 297
  time since seroconversion estimation, 1753
Akaike's information criterion (AIC)
  age at menopause genetic analysis, 1217
  covariance structure modelling, 1793
  monotonic non-linear model, 2053
  multi-state model, 3465
  prognostic factors with censored data, 601
  prognostic modelling, 1059
  robust mixed linear model, 975
  spatio-temporally misaligned data, 2265
all subsets regression, prognostic models, 453
allografting, leukaemia-free survival, 3005
alpha calculus, 767, 781, 785, 795
alpha control, secondary endpoints, 763, 767, 781, 785, 795
alternating conditional sampling algorithm, HIV infection risk, 2641
Alzheimer's disease
  change point model, 1555
  cognitive change measurement, 1421
  cognitive tests reliability, 1411
  community-based studies, 1469
  database design, 1531
  decline pattern, 1593
  dementia subtypes incidence, 1577
  differential item functioning, 1651
  follow-up waves spacing, 1567
  incidence estimation, 1495
  incidence and prevalence projection, 1481
  item response theory, 1631
  level and longitudinal rate of change, 1441
  longitudinal studies, 1401, 1433
  mini mental state examination changes, 1607
  mixed effects models, 1617
  odds ratio estimation, 1523
  progression measurement, 1393
  scientists and clinicians interaction, 1453, 1463
  screening tests, 1697
  smoking and drinking influence, 1685
  Special Issue, 1389
  two-phase surveys, 2101
Alzheimer's Disease Assessment Scale (ADAS), 1401
Alzheimer's Disease Centres, 1453, 1463, 1531
Amsterdam cohort study, time since seroconversion estimation, 1753
anaemia, head and neck cancer effects, 1237
Andersen and Gill model (AG), 13
angular transformation, ratio estimation, 2989

*Author and subject indexes were compiled by Indexing Specialists, 202 Church Road, Hove, East Sussex BN3 2DJ, UK

antedependence test, post-operative pain, 1889
antidepressant clinical trials, time to onset of response, 2169
approximate Bayesian bootstrap (ABB), interval censored data, 1
area under the curve
  bioequivalence, 2769, 2811, 2821, 2843, 2855
  individual bioequivalence, 2775
  messy longitudinal data, 2657
  post-operative pain, 1889
area under ROC curve
  see also receiver operating characteristic (ROC) curves
  diagnostic markers effectiveness, 2115
  prognostic modelling, 1059
  tumour staging and grading systems, 1997
areal data, disease mapping, 2203
artificial neural networks, prognostic and diagnostic classification, 541
Aspirin Myocardial Infarction Study (AMIS), 2919
association studies, statistical genetics, 3337
asthma
  spatial model selection, 1915
  spatio-temporally misaligned data, 2265
asymmetric sigmoid curves, monotonic non-linear model, 2053
asymptotic test, non-inferiority, 2089
asymptotic trend test, power comparisons, 3037
attributable risk, confidence intervals, 1089
auto-Poisson model, disease mapping, 2539
autocorrelated errors, joinpoint regression, 335
autocorrelation, robust mixed linear model, 975
autoregressive covariance structure, covariance structure modelling, 1793
AVE test, unbalanced factorial design clinical trials, 2079
average bioequivalence, 2719, 2721, 2741, 2769, 2811, 2821, 2843, 2879
average squared error, Monte Carlo, 389

B-tests, age-specific reference intervals, 2943
back pain, cost data analysis, 3219
back-calculation
  age-specific incidence, 281
  AIDS incubation time uncertainty, 175
  HIV & AIDS epidemics reconstruction, 161
  HIV & AIDS surveillance data, 297
back-projection, HIV incidence rates estimation, 1165
back-propagation algorithm, prognostic and diagnostic classification, 541
backward elimination, smoking and drinking interactions, 1685
backwards stepwise selection, prognostic modelling, 1059
barrier methods, transitional model, 71
baseline hazards, Cox-based recurrent event model, 13
baseline measurement, role, 861
baseline risk
  meta-analysis, 3497
  non-compliance and sample size, 2689
Bayes theorem
  scoring systems, 575
  sensitivity and specificity, 1783
  space-time mixture modelling, 2333
Bayesian bootstrap, approximate, 1
Bayesian decision-making, evidence-based medicine, 3291
Bayesian graphical models, foetal loss familial tendency, 2147
Bayesian hierarchical models
  disease mapping, 2493, 2539
  generalized synthesis of evidence, 3359
  longitudinal biomarkers, 617
  spatio-temporal interaction, 2015
Bayesian hierarchical spatial model, probabilistic small area risk assessment, 2345
Bayesian information criterion (BIC)
  cluster modelling, 2361
  interval censored data, 2611
Bayesian intensity model, age-specific incidence back-calculation, 281
Bayesian methods
  accelerated failure time analysis, 221
  Alzheimer's disease cognitive tests, 1411
  disease mapping, 957, 2203, 2217
  disease prevalence, 681
  false-positive cumulative risk, 1865
  fertility studies, 665
  generalized population attributable fraction, 937
  headbanging algorithm, 2309
  HIV infection risk, 2641
  journal trends, 3275
  longitudinal studies with continuous outcomes, 1339
  meta-analysis, 3251, 3497
  missing covariate values, 1237
  partition structures, 2579
  quality of life, 3237
  risk factor assessment, 1523
  robust empirical, 975
  small area disease risks, 2409
  space-time models, 2569
  space-time variation, 2555
  spatial models, 1915, 2279
  spatio-temporally misaligned data, 2265
Bayesian predictive inference, group sequential designs, 3023

Bayesian random effects models, age at menopause genetic analysis, 1217
Behavior Observation Rating (BOR), 1593
behavioural rating scales, Alzheimer's disease, 1393
Bernoulli likelihood, fertility studies, 665
Bernstein-Lagakos formula, 441
Besag and Newell's general test, clustering, 1363
Besag, York and Mollie (BYM) model, disease mapping, 2217
best linear unbiased estimates (BLUE), covariance structure modelling, 1793
best linear unbiased predictors (BLUPs)
  Alzheimer's disease, 1421
  random effects models, 1265
  treatment comparison, 1115
beta-binomial model, risk ratio confidence intervals, 2933
beta-binomial random effect model, rheumatoid vasculitis, 3433
Beth Israel Deaconess Medical Center, Biometrics Center, 2131
between-subjects variability, robust mixed linear model, 975
bias
  Blomqvist method, 1441
  censored biomarker measurements, 3171
  differential item functioning, 1651
  ecological studies, 45
  generalized linear model predictive power, 1771
  longitudinal Alzheimer's disease, 1617
  meta-analysis, 3251, 3325
  randomized clinical trials treatment effects, 1849
  screening tests, 1697
  time trends in adaptive designs, 2067
bias corrected and accelerated method, bootstrap confidence intervals, 1141
bias corrected bootstrap, cost data analysis, 3219
bias corrected method, bootstrap confidence intervals, 1141
binary item response theory, differential item functioning, 1651
binary logistic model, continuation ratio random effects model, 3377
binary logistic regression, messy longitudinal data, 2657
binary outcomes
  meta-analysis, 1707, 3417
  multi-level model, 2675
  non-compliance and sample size, 2689
binary responses
  GEE analysis, 715
  multi-centre data, 1115
binomial data, exact sequential tests, 3051
binomial regression, Bayesian accelerated failure time analysis, 221
bioequivalence
  see also average bioequivalence; individual bioequivalence; population bioequivalence
  Special Issue, 2719
  total deviation index, 255
biomarkers
  censored measurements, 3171
  longitudinal, 617
  trajectories, latent class mixed model, 1303
birth
  meta-analysis, 3497
  preterm delivery risk factors, 1089
  prevalence, delayed onset disorders, 743
  sex ratio, additive isotonic regression models, 849
  weight
    generalized linear model predictive power, 1771
    lung disease, 937
    pregnancy risks, 239
    spatial filters, 2399
bivariate latent class model, 35
bivariate survival, conditional models, 563
Blessed Dementia Rating Scale (BDRS), 1411
Blessed Information Memory Concentration Test, 1631
Blessed-Roth Dementia Rating Scale, 1631
Blomqvist method, Alzheimer's disease, 1441
blood pressure
  adult predictions, 2625
  continuous covariates modelling effect, 1831
  monotonic non-linear model, 2053
BLUPs *see* best linear unbiased predictors
bone density, longitudinal studies with continuous outcomes, 1339
bone marrow transplantation, leukaemia-free survival, 3005
bone mineral density, group sequential longitudinal trials, 205
Bonferroni correction
  joinpoint regression, 335
  multiple comparisons, 369
  prognostic variable categorization, 113
book reviews
  Abdi, H., Valentin, D. and Edelman, B., *Neural Networks*, 2199
  Adam, J. A. and Bellomo, N. (eds), *A Survey of Models for Tumor-Immune System Dynamics*, 3140
  Armitage, P. and Colton, T. (eds), *Encyclopedia of Biostatistics*, 1255
  Azzalini, A., *Statistical Inference Based on the Likelihood*, 1260
  Barnett, V., Stein, A. and Feridun Turkman, K. (eds), *Statistics for the Environment 4. Statistical Aspects of Health and the Environment*, 1824

Bernardo, J. M., Berger, J. O., Dawid, A. P. and Smith, A. F. M. (eds), *Bayesian Statistics 6.*, 3143
Brillinger, D. R., Fernholz, L. T. and Morgenthaler, S. (eds), *The Practice of Data Analysis: Essays in Honor of John W. Tukey*, 884
Cheng, C.-L. & Van Ness, J. W, *Statistical Regression with Measurement Error*, 2077
Chow, S.-C. & Liu, J.-P. (eds), *Design and Analysis of Animal Studies in Pharmaceutical Development*, 1953
Chow, S.-C. and Liu, J.-P., *Design and Analysis of Clinical Trials*, 3021
Clarke, G. M. and Kempson, R. E., *Introduction to the Design and Analysis of Experiments*, 882
Cliff, A., Haggett, P. and Smallman-Raynor, M., *Deciphering Global Epidemics: Analytical Approaches to the Disease Records of World Cities 1888-1912*, 2715
Cox, D. R. and Wermuth, N., *Multivariate Dependencies. Models, Analysis and Interpretation*, 277
Cruickshante, S., *Mathematics and Statistics in Anaesthesia*, 1385
Day, S., *Dictionary for Clinical Trials*, 3144
Draper, N. R. and Smith, H., *Applied Regression Analysis* 3rd edn, 3136
Dryden, I. L. and Mardia, K. V., *Statistical Shape Analysis*, 2716
Everitt, B. S. and Dunn, G. (eds), *Statistical Analysis of Medical Data. New Developments*, 1828
Everitt, B. S., Dunn, G. and Holford, T. R. (eds), *Statistical Methods in Medical Research: The Statistics of Smoking*, 1379
Ferlay, J., Parkin, D. M. and Pisani, P., *Globocan 1: Cancer Incidence and Mortality Worldwide*, 2714
Firebaugh, G., *Analyzing Repeated Surveys*, 1951
Gad, S. C., *Statistics and Experimental Design for Toxicologists*, 2077
Gamerman, D., *Markov Chain Monte Carlo: Stochastic Simulation for Bayesian Inference*, 883
Gerstman, B. B., *Epidemiology Kept Simple: An Introduction to Classic and Modern Epidemiology*, 1005
Gower, J. C. and Hand, D. J., *Biplots*, 278
Greenfield, T. (ed), *Research Methods - Guidance for Postgraduates*, 3020
Gregoire, T. G., Brillinger, D. R., Diggle, P. J., Russek-Cohen, E., Warren, W. G. and Wolfinger, R. D. (eds), *Modeling Longitudinal and Spatially Correlated Data: Methods, Applications and Future Directions*, 1258
Haberman, S. and Pitacco, E., *Actuarial Models for Disability Insurance*, 1381
Hargrove, J. L., *Dynamic Modeling in the Health Sciences*, 3142
Hollander, M. and Wolfe, D. A., *Nonparametric Statistical Methods*, 1386
Hosmer, D. W. and Lemeshow, S., *Applied Survival Analysis. Regression Modeling of Time to Event Data*, 1823
Hsu, J. C., *Multiple Comparisons - Theory and Methods*, 1951
Jorgensen, B., *The Theory of Dispersion Models*, 1952
Kanji, G. K., *100 Statistical Tests*, 3018
Klinke, S., *Data Structures for Computational Statistics*, 3019
Koornwinder, T. H. (ed), *Wavelets: An Elementary Treatment of Theory and Applications*, 1009
Krickeberg, K., *Petit Cours de Statistique*, 275
Krzanowski, W. J., *An Introduction to Statistical Modelling*, 1380
Lange, K., *Mathematical and Statistical Methods for Genetic Analysis*, 1947
Lindsey, J. K., *Revealing Statistical Principles*, 3022
Neuilly, M., *Modelling and Estimation of Measurement Error*, 1827
Parkin, D. M., Whelan, S. L., Ferlay, J., Raymond, L. and Young, J. (eds), *Cancer Incidence in Five Continents Vol VII*, 1261
Pereira-Maxwell, F., *A-Z of Medical Statistics: A Companion for Critical Appraisal*, 1257
Rao, P. S. R. S., *Variance Components Estimation*, 1008
Rothman, K. J. and Greenland, S., *Modern Epidemiology* 2nd ed, 881
Royall, R., *Statistical Evidence: A Likelihood Paradigm*, 879
Schafer, J. L., *Analysis of Incomplete Multivariate Data*, 1006
Schnabel, M., *Expertensysteme in der Medizin - Eine Einführung mit Beispielen*, 1949
Sham, P., *Statistics in Human Genetics*, 1384
Staquet, M. J., Hays, R. D. and Fayers, P. M. (eds), *Quality of Life Assessment in Clinical Trials: Methods and Practice*, 1382
Stuart, A., Ord, K. and Arnold, S., *Kendall's Advanced Theory of Statistics. Volume 2A: Classical Inference and the Linear Model*, 3139
Thompson, M. E., *Theory of Sample Surveys*, 1825
Vermunt, J. K., *Log-linear Models for Event Histories*, 1263

Waller, N. G. and Meehl, P. E., *Multivariate Taxometric Procedures*, 2713
Winkelmann, R., *Econometric Analysis of Count Data* 2nd ed., 276
Zelterman, D., *Models for Discrete Data*, 1829
bootstrap
AIDS incubation time uncertainty, 175
approximate Bayesian, 1
attributable risk confidence intervals, 1089
bioequivalence, 2769, 2811
Canadian Cancer Incidence Atlas, 2437
cluster randomized trial, 2675
conditional autoregressive models, 2421
confidence intervals, 313, 1141
cost data analysis, 3219
cost-effectiveness analysis, 2989
diagnostic markers/repeated measurements comparison, 511
generalized linear model predictive power, 1771
individual bioequivalence, 2741, 2775, 2797, 2885
interval censored data survival function, 2611
latent class mixed model, 1303
meta-analysis, 3417
multi-state models, 587, 3465
percentile method, 1141
individual bioequivalence, 2741
profile similarity, 2855
prognostic models, 141
ROC curves, 493
screening tests verification bias, 1697
time since seroconversion estimation, 1753
time to onset of response, 2169
tree stability diagnostics, 475
tumour staging and grading systems, 1997
bootstrap-*t*, 1141
cost data analysis, 3219
individual bioequivalence, 2741
Box-Tidwell model, monotonic non-linear model, 2053
Box-Tidwell power curves, continuous covariates modelling effect, 1831
Bradford Hill Memorial Lecture, 3149
breast cancer
cluster randomized trial, 2675
continuation ratio random effects model, 3377
cubic smoothing spline models, 1191
cumulative cause-specific mortality, 1729
diagnostic markers/repeated measurements comparison, 511
false-positive cumulative risk, 1865
generalised synthesis of evidence, 3359
interval censored data, 1, 2611
interval censored data hazard function, 405
linear mixed effects models, 2251
monotonic non-linear model, 2053
prevention trials design, 1983
prognostic factors with censored data, 601
subpopulation treatment effect pattern plot, 2595
tree stability diagnostics, 475
Brier score, tumour staging and grading systems, 1997
British Medical Journal, 3149
bronchitis, space-time models, 2569
Buschke Selective Reminding test, 1555

calibration, prognostic survival models, 3401
Canadian Cancer Incidence Atlas, 2437
Canadian Study of Health and Aging, 1685
cancer
attributable risk confidence intervals, 1089
breast
cluster randomized trial, 2675
continuation ratio random effects model, 3377
cubic smoothing spline models, 1191
cumulative cause-specific mortality, 1729
diagnostic markers/repeated measurements comparison, 511
false-positive cumulative risk, 1865
generalised synthesis of evidence, 3359
interval censored data, 1, 2611
interval censored data hazard function, 405
linear mixed effects models, 2251
monotonic non-linear model, 2053
prevention trials design, 1983
prognostic factors with censored data, 601
subpopulation treatment effect pattern plot, 2595
tree stability diagnostics, 475
Canadian Cancer Incidence Atlas, 2437
conditional models in bivariate survival, 563
group sequential longitudinal trials, 205
head, anaemia effects, 1237
incidence prediction, 1741
joinpoint regression, 335
larynx, disease mapping, 2493
leukaemia, cluster probability due to chance, 2195
lip
Bayesian disease mapping, 2579
disease mapping, 957
posterior predictive model checks, 2377
spatial model selection, 1915
lung
messy longitudinal data, 2657
proportional hazards model, 3309
risk of smoking, 2185
space-time mixture modelling, 2333
space-time variation, 2555
spatio-temporal interaction, 2015
triple-goal estimates, 2295

multiple treatment courses evaluation, 1011
neck, anaemia effects, 1237
non-Hodgkin's lymphoma, prognostic survival models, 3401
ovarian, prognostic factors sample size, 441
prevention trials design, 1983
prognostic and diagnostic classification, 541
prognostic variable categorization, 113
prostate
cumulative cause-specific mortality, 1729
inference on a collapsed margin, 2243
latent class mixed model, 1303
longitudinal biomarkers, 617
multiple treatment courses, 1011
random effect selection model, 3237
rectal, sequential analysis, 3449
ROC curves regional confidence bands, 493
tumour response and survival, 837
tumour staging and grading systems, 1997
capture-recapture methods, vaccine efficacy estimation, 827
carcinogenesis study, multiple comparisons, 353
caregivers, group sequential longitudinal trials, 205
Carstairs index, disease mapping, 2493
CART
prognostic models, 453
tree stability diagnostics, 475
cartograms, disease mapping, 2203
case deletion diagnostics, accelerated failure time analysis, 221
case-control studies
attributable risk confidence intervals, 1089
matching, 35
pair-matched, 923
paired organs, 525
sequential analysis, 3449
smoking and lung cancer, 2185
categorical repeated measurements, conditional models, 801
censored biomarker measurements, analysis and design, 3171
censored data, prognostic factors, 601
census regression coefficients, community-based studies, 1469
CERAD *see* Consortium to Establish a Registry for Alzheimer's Disease
change point model
Alzheimer's disease, 1555
longitudinal biomarkers, 617
chi-square, malaria risk factors, 1931
chickenpox, SEIR model, 1207
childhood infectious diseases, survival analysis, 13
chloropleth maps
disease mapping, 2203
epidemiology, 2521
space-time mixture modelling, 2333
cholesterol
meta-analysis, 3497
randomized clinical trials treatment effects, 1849
chronic granulotomous disease (CGD), proportional hazards model, 3309
chronic obstructive pulmonary disease (COPD), 2521
chunking, smoking and drinking interactions, 1685
circulatory disease, multivariate spatial models, 2469
cirrhosis, meta-analysis, 3251
classical weighted least squares (CWLS), 2919
Clinic for Alzheimer Disease and Related Disorders, 1685
Clinical Dementia Rating (CDR), Alzheimer's disease, 1393, 1433
closed multiple testing procedure, 353
cluster evaluation permutation procedure, 1363
cluster modelling, RJMCMC methods, 2361
cluster probability, due to chance, 2195
cluster process model, rheumatoid vasculitis, 3433
cluster randomized trials
journal trends, 3275
multi-level model, 2675
cluster sampling, risk ratio, 2933
clustered failure time data, permutation tests, 2963
clustered survival data,proportional hazards model,3309
clustering
spatial disease clustering, 191
tests comparison, 1363
cocaine, stroke risk, 99
Cochran-Armitage test, power comparisons, 3037
Cochran-Mantel-Haenszel statistic, messy longitudinal data, 2657
Cochrane Pregnancy and Childbirth Database, 1707
coefficient of determination, dichotomous outcomes, 271
cognitive assessment measures, differential item functioning, 1651
cognitive change measurement, Alzheimer's disease, 1421
cognitive tests, Alzheimer's disease, 1393, 1411
Cohen-Sackrowitz exact test, power comparisons, 3037
Cohen's kappa, interval estimation, 723
cohort studies
decline pattern modelling, 1593
Monte Carlo, 2933
time since seroconversion estimation, 1753
collapsed margin, disease mapping, 2243
colorectal hepatic metastases, random effect selection model, 3237
combination drug trials, unbalanced factorial design clinical trials, 2079

community populations, parametric empirical Bayes estimation, 681
community-based studies, Alzheimer's disease, 1469
comparative biomedical studies, optimal treatment allocation, 639
comparative calibration, without a gold standard, (Letter) 1253
comparative incidence figure (CIF), Canadian Cancer Incidence Atlas, 2437
competing risks failure time methods, vaccine protection, 3065
compliance
  sample size, 2689
  transitional model, 71
computer packages
  bootstrap confidence intervals, 1141
  boxtid, 2053
  BUGS, 957, 1217, 1915, 2147, 2409, 2569, 3237, 3359, 3497
  CAMAN, 2539
  CODA, 2147
  covariance structure modelling, 1793
  differential item functioning, 1651
  directed vertex peeling, 2699
  DismapWin, 2539
  FORTRAN, 2775
  FoxPro, 1645
  incidence and prevalence projection, 1481
  meta-analysis, 1707, 3251
  MLwiN, 2469, 2675, 3237, 3417
  PEST, 3449
  recurrent event data, 13
  S-plus, 1059
  SAS, 1115, 1265, 1277, 1339, 1495, 2775, 3171
  SAS PROC MIXED, 1101, 1441, 2251, 3497
  Stata, 2053
  StatXact, 2089
  Stuttgart Neural Network Simulator, 541
  WinBUGS, 2493
concordance
  individual bioequivalence, 2721
  ratings using different scales, 3483
  tumour staging and grading systems, 1997
concordance correlation coefficient, 255, 1265
concordance index, generalized linear models goodness-of-fit, 1265
conditional approach, paired organs, 525
conditional autoregressive (CAR) models
  bootstrap, 2421
  disease mapping, 957, 2539
  environmental pollution, 2569
  penalized quasi-likelihood, 2421
  spatial models, 1915, 2279
  spatio-temporally misaligned data, 2265
conditional likelihood
  loss to follow-up, 71
  matched case-control data, 35
conditional mean squared error of prediction (CMSEP), 1115
conditional models
  bivariate survival, 563
  categorical repeated measurements, 801
  marginal estimates, 801
conditional power method, group sequential designs, 3023
conditioned chloropleth maps, 2521
confidence intervals
  area under ROC curves, 2115
  attributable risk, 1089
  bootstrap, 313, 1141
  correlated binary proportions, (Letter) 133
  cost data analysis, 3219
  generalized treatment effects, 887
  group sequential designs, 3023
  individual bioequivalence, 2885
  journal trends, 3275
  model-robust quantal regression, 389
  placebo-challenging designs, 1029
  risk ratio under cluster sampling, 2933
  ROC curves, 45
  screening tests verification, 1697
confidence profiling method, 3359
confirmatory factor analysis, differential item functioning, 1651
confounding, randomized clinical trials treatment effects, 1849
Consortium to Establish a Registry for Alzheimer's Disease (CERAD), 1393, 1441, 1593, 1607
constant hazards model, follow-up waves spacing, 1567
constant-scaled method, 2821, 2885
constrained Bayes, triple-goal estimates, 2295
contact rate, SEIR model, 1207
contingency table analysis, generalized Rudas-Clogg-Lindsay index of fit, 1881
continuation ratio model, scoring systems, 575
continuation ratio random effects model, repeated ordinal responses, 3377
continuous covariates, modelling effect, 1831
continuous outcomes, quality control measure, 1339
contrast-based test, dose response, 913
Cornish-Fisher expansion, bioequivalence, 2885
coronary stents, 3149
correlated binary proportions, confidence intervals, (Letter) 133
cost data analysis, randomized trials, 3219
cost-effectiveness analysis, angular transformation, 2989

covariance methods, randomized clinical trials, 1039
covariance structure modelling, Tutorial in Biostatistics, 1793
covariate imbalance, logrank test, 1955
Cox proportional hazards model
see also proportional hazards
age at menopause genetic analysis, 1217
cubic smoothing spline models, 1191
prognostic factors sample size, 441
recurrent event data, 13
treatment-covariate interactions, 2595
tumour response and survival, 837
vaccine protection, 3065
Cox regression
age at menopause genetic analysis, 1217
false-positive cumulative risk, 1865
multi-state models, 587
oral candidiasis episodes, 989
prognostic survival models, 3401
Cox's partial likelihood, Alzheimer's disease, 1495
Cramer-von Mises test, time to onset of response, 2169
Cramer's *V*-value test, malaria risk factors, 1931
cross-cultural study, data management, 1645
cross-design synthesis, 3359
cross-over designs
bioequivalence, 2885
individual bioequivalence, 2721, 2741, 2775, 2811, 2821, 2843, 2867
cross-sectional studies, age-related trends, 697
cross-validation
differential item functioning, 1651
generalized linear model predictive power, 1771
interval censored data, 2611
posterior predictive model checks, 2377
cubic smoothing spline models
continuous covariates modelling effect, 1831
scale choice, 1191
cumulative cause-specific mortality, cancer patients, 1729
cumulative risk, repeated screening events, 1865
cumulative-odds model, scoring systems, 575
cure model, time to onset of response, 2169
cure rate models, group sequential designs, 3023
curve-fitting, continuous covariates modelling effect, 1831
cutaneous malignant melanoma, attributable risk confidence intervals, 1089
cyclic pool adjacent violators (PAV) algorithm, 849
cystic fibrosis, delayed onset disorders birth prevalence, 743

data management, longitudinal cross-cultural study, 1645
Data Monitoring Centre, 3389
Data and Safety Monitoring Board, 2899
database design, balanced, centralized and distributed, 1531
delayed onset disorders, birth prevalence, 743
delta method
attributable risk confidence intervals, 1089
spatio-temporally misaligned data, 2265
dementia
see also Alzheimer's disease
change point model, 1555
data management, 1645
follow-up waves spacing, 1567
global functioning measure, 1631
screening tests, 1697
subtypes incidence estimation, 1577
two-phase sampling, 1545
Dementia Rating Scale, Alzheimer's disease, 1421
density equalizing map projection (DEMP), disease mapping, 2203
depression, internal pilot studies, 901
deviance information criterion (DIC), spatio-temporally misaligned data, 2265
diabetes
non-parametric test of ordered alternatives, 1329
probabilistic small area risk assessment, 2345
diabetic retinopathy, GLM residuals analysis, 1277
diagnostic classification, artificial neural networks, 541
diagnostic markers
measurement error, 2115
repeated measurements comparison, 511
diagnostic measurements, paired organs, 525
diagnostic power, prevalence-free utility-respecting summary indices, 431
diagnostic tests
comparison, 649
sensitivity and specificity, 1783
dichotomous outcomes, coefficient of determination, 271
dichotomous response logistic model, 1651
differential item functioning, psychometric methods, 1651
dioxin elimination, longitudinal data with truncated observations, 2975
directed acyclic graph (DAG), foetal loss familial tendency, 2147
directed vertex peeling (DVP), ordered categorical data, 2699
disaggregate criterion
bioequivalence, 2769, 2821
of population bioequivalence, 2755
discrete responses, exact sequential tests, 3051
discrete scale, concordance, 3483

discrete-time model, HIV & AIDS surveillance data, 297
discriminant analyses, 525
disease mapping
  artefacts quantification, 2309
  Bayesian analysis, 957
  Bayesian modelling, 2555, 2579
  Canadian Cancer Incidence Atlas, 2437
  conditional autoregressive models, 2421
  deviance information criterion, 2265
  empirical Bayes, 2409
  empirical evaluation, 2217
  environmental pollution, 2569
  epidemiology applications, 2521
  evaluation focus Special Issue, 2201
  inference on a collapsed margin, 2243
  Markov chain Monte Carlo, 2279
  maximum likelihood, 2321
  method classification, 2203
  multiregion contact systems, 2479
  multivariate spatial models, 2469
  non-parametric MLE, 2539
  posterior predictive model checks, 2377
  RJMCMC methods, 2361
  small area risk assessment, 2345
  space-time mixture models, 2333
  spatial competing risk models, 2451
  spatial filters evaluation, 2399
  spatio-temporal interaction, 2015
  spatio-temporal patterns, 2251
  triple-goal estimates, 2295
disease onset, longitudinal biomarkers, 617
disease prevalence
  Bayesian approach, 681
  estimation, two-phase surveys, 2101
disease-free equilibrium (DFE), multiregion contact systems, 2479
Donolo-Tel Aviv Three Generation Offspring Study, 3345
donor lymphocyte infusions, leukaemia-free survival, 3005
dose effects, dose-response studies, 3037
dose-response relationship, ecological bias, 45
dose-response studies
  with contrasts, 913
  optimal treatment allocation, 639
  power, 3037
  semiparametric approach, 389
double Laplace-Metropolis method, spatial model selection, 1915
double saddlepoint approximation, 323
doubly censored data, 3171
drinking, Alzheimer's disease, 1685
drug development, statistical thinking role, 3211
drug use
  HIV infected individuals estimation, 3095
  HIV infection risk, 2641
Duchenne muscular dystrophy, diagnostic markers effectiveness, 2115
dynamic mixtures, space-time mixture modelling, 2333

early stopping
  group sequential designs, 3023
  sequential analysis, 3449
ecological studies, bias, 45
effect size
  measures, interpretability, 1295
  odds ratio conversion, 3127
EM algorithm
  Alzheimer's disease, 1441
  disease mapping, 2539
  Gaussian repeated measures, 1101
  generalized Rudas-Clogg-Lindsay index of fit, 1881
  HIV & AIDS surveillance data, 297
  interval censored data hazard function, 405
  latent class mixed model, 1303
  longitudinal biomarkers, 617
  multiple imperfect assessments, 99
  patient-specific analysis, 83
  proportional hazards model, 3309
  random effect selection model, 3237
  risk factor assessment, 1523
  space-time mixture modelling, 2333
  triple-goal estimates, 2295
  two-phase sampling, 1545
empirical Bayes
  Alzheimer's disease, 1421
  cognitive tests reliability, 1411
  community-based studies, 1469
  disease mapping, 2539
  HIV-infection estimation, 3095
  longitudinal studies with continuous outcomes, 1339
  posterior predictive model checks, 2377
  quality of life, 3237
  robust, 975
  small area disease risks, 2409
  space-time mixture modelling, 2333
  spatio-temporally misaligned data, 2265
  triple-goal estimates, 2295
empirical cumulative distribution functions (ECDF), 1753
empirical distribution function (EDF), triple-goal estimates, 2295
EMS algorithm, HIV incidence rate estimation, 1165

endpoints, secondary, alpha control, 763, 767, 781, 785, 795
environmental pollution, space-time models, 2569
epidemics reconstruction, HIV/AIDS, 161
epidemiology
  additive isotonic regression models, 849
  Bayesian accelerated failure time analysis, 221
  pharmaceutical industry, 3193
equivalent degrees of freedom, continuous covariates modelling effect, 1831
erectile dysfunction, placebo-challenging designs, 1029
error
  see also type I error; type II error
  HIV/AIDS epidemics reconstruction, 161
estimated variance component, subject-by-formulation interaction, 2867
event data
  multivariate spatial models, 2469
  safety monitoring, 2899
events per variable (EPV), 453
evidence-based medicine (EBM)
  Bayesian decision-making, 3291
  journal trends, 3275
exact sequential tests, discrete responses, 3051
exact tests
  dose-response studies, 3037
  non-inferiority, 2089
exploratory analysis, sliding time windows, 2185
exponential curves, continuous covariates modelling effect, 1831
exponential decay model, Alzheimer's disease, 1401
external validity, 3149

factorial design clinical trials, unbalanced, 2079
failure time analysis, Bayesian accelerated, 221
failure time data, permutation tests, 2963
failure time mixture model, missing covariate values, 1237
familial associations of lipid profiles, GEE approach, 3345
feed-forward neural networks, prognostic and diagnostic classification, 541
fertility studies, missing data, 665
finite population sampling, community-based studies, 1469
fitted growth curve model, Alzheimer's disease, 1401
fixed effects
  cluster summary statistics, 2675
  covariance structure modelling, 1793
  disease mapping, 2217
  meta-analysis, 1707
  treatment comparison, 1115
foetal loss familial tendency, Bayesian graphical models, 2147
follow-up waves spacing, incidence studies, 1567
Food and Drug Administration (FDA)
  bioequivalence guidance, 2755, 2769, 2811, 2821, 2867, 2879, 2885
  bootstrap, 2741
  data set, 2721, 2775
  individual bioequivalence guidance, 2719
fractional polynomials
  continuous covariates modelling effect, 1831
  cubic smoothing spline models, 1191
frailty
  bivariate survival, 563
  continuation ratio random effects model, 3377
frailty models, 13, 3309
fully-homoscedastic model, unbalanced longitudinal data, 1969

gamma, effect size measures interpretability, 1295
gamma-Poisson exchangeable model, disease mapping, 2217
gamma-Poisson model, space-time mixture modelling, 2333
gap time - unrestricted (GT-UR) model, 13
gap time model, 13
gastrointestinal bleeding, meta-analysis, 3417
Gauss-Hermite quadrature approximation, 1115
Gauss-Seidel procedure, monotonic non-linear model, 2053
Gaussian intrinsic autoregression and white noise (GIARWN), 2409
Gaussian Markov random field (GMRF), small area disease risks, 2409
Gaussian models, disease mapping, 2279
Gaussian regression model, ecological studies, 45
Gaussian repeated measures, missing data, 1101
Gehan's test, 353, 3171
Geisser-Greenhouse corrected univariate test, 1101
gene mapping, 3337
general linear multivariate model, Gaussian repeated measures, 1101
generalised synthesis of evidence, hierarchical models, 3359
generalized additive model smoothing, HIV & AIDS surveillance data, 297
generalized correlation models, rheumatoid vasculitis, 3433
generalized EM algorithm, latent class mixed model, 1303
generalized estimating equations (GEE)
  age at menopause genetic analysis, 1217
  cluster randomized trial, 2675
  familial associations of lipid

Gaussian repeated measures, 1101
group sequential longitudinal trials, 205
messy longitudinal data, 2657
negatively correlated binary
paired organs, 525
residuals analysis, 1277
generalized least squares
community-based studies, 1469
covariance structure modelling, 1793
generalized linear mixed models (GLMM)
disease mapping, 957
environmental pollution, 2569
spatial disease rates, 2321
generalized linear models
goodness-of-fit, 1265
population attributable fraction, 937
predictive power, 1771
residuals analysis, 1277
generalized linear rank test statistic, marginal survival functions, 2963
generalized logit transitional regression model, 71
generalized population attributable fraction, Bayesian inference, 937
generalized removal model, HIV infected individuals estimation, 3095
generalized Rudas-Clogg-Lindsay index of fit, rater agreement, 1881
generalized Steel's test, multiple comparisons, 353
generalized treatment effects, clinical trials, 887
genetic analysis, age at menopause, 1217
genetic epidemiology, multi-stage sampling (Correction), 1251
genetics, future directions, 3337
geographic information systems (GIS)-based data, probabilistic small area
German Society for Medical Informatics, Biometry and Epidemiology (GMDS), 3307
Gibbs sampling
age at menopause genetic analysis, 1217
disease mapping, 957, 2539
false-positive cumulative risk, 1865
foetal loss familial tendency, 2147
generalised synthesis of evidence, 3359
HIV infected individuals estimation, 3095
longitudinal biomarkers, 617
meta-analysis, 3251, 3497
missing covariate values, 1237
proportional hazards model, 3309
space-time models, 2569
spatial models, 2279
glaucoma, diagnostic measurements, 525
global cross ratio model, r x k tables, 1901
Global Deterioration Scale, Alzheimer's disease, 1393
global functioning measure, with linear measurement properties, 1631
global tests, unbalanced factorial design clinical trials, 2079
Gompertz growth curves, 2053
Goodman-Kruskal's gamma, 3483
goodness-of-fit
age-specific reference intervals, 2943
cluster modelling, 2361
continuous covariates modelling effect, 1831
delayed onset disorders birth prevalence, 743
differential item functioning, 1651
disease mapping, 2217
generalized linear models, 1265
generalized Rudas-Clogg-Lindsay index of fit, 1881
Monte Carlo, 373
muscle biopsy specimens, 3433
randomized clinical trials, 1039
seasonal SEIR models, 1207
treatment comparison, 1115
G^{ρ} tests, interval censored data, 1
GP-IIIa polymorphism Pl^{A2}, pair-matched case-control study, 923
grid search method, joinpoint regression, 335
grid tests, age-specific reference intervals, 2943
group sequential designs, cure rate models, 3023
group sequential longitudinal trials, sample size, 205
grouped continuous logistic regression, scoring systems, 575
growth curve models
Alzheimer's disease, 1401
decline pattern modelling, 1593

haematological data, patient-specific analysis, 83
Haemophilus influenzae Type b, age-specific incidence back-calculation, 281
harmonic mean, spatial model selection, 1915
Harrell's index, 431
hazard function, interval censored data, 405
head cancer, anaemia effects, 1237
head injuries
safety monitoring, 2899
scoring systems, 575
headbanging algorithm, disease mapping, 2309
heart disease
familial associations of lipid profiles, 3345
non-compliance and sample size, 2689
heart failure
cost-effectiveness analysis, 2989
generalized treatment effects, 887
pair-matched case-control study, 923
prognostic modelling, 1059
six-minute walking test reproducibility, 3087

Hepatic Artery Pump trial, 3237
heterogeneity, meta-analysis, 1707
hierarchical backward elimination, smoking and drinking interactions, 1685
hierarchical linear models, longitudinal studies with continuous outcomes, 1339
hierarchical models, 861
  see also Bayesian hierarchical models
  generalised synthesis of evidence, 3359
  space-time mixture modelling, 2333
  spatio-temporally misaligned data, 2265
  triple-goal estimates, 2295
hierarchical multiple regression, patient-specific analysis, 83
HIV
  AIDS incubation time uncertainty, 175
  epidemics reconstruction, 161
  HSV-2 observational studies, 3193
  incidence rates estimation, 1165
  infected individuals estimation, 3095
  infection risk, 2641
  interval censored data hazard function, 405
  multiregion contact systems, 2479
  surveillance data, back-calculation, 297
  time since seroconversion estimation, 1753
  vaccine trial, 3065
  viral load measurements, 3171
homogeneity, risk ratio, 2919
homoscedastic model, unbalanced longitudinal data, 1969
Honolulu-Asia Aging Study, 1577
Hotelling-Lawley trace test, 1101
Howe's approximation I, bioequivalence, 2885
Human Genome Project, 3337
hybrid bootstrap, individual bioequivalence, 2741
hypertension, meta-analysis, 3497
Hypertension Detection and Follow-up program trial, 2963

importance sampling, generalized population attributable fraction, 937
incidence
  Alzheimer's disease, 1481, 1495
  dementia, 1545
  dementia subtypes, 1577
  follow-up waves spacing, 1567
  interpolation techniques, 1741
incidence density analyses, non-parametric covariance methods, 1039
incidence-free utility-repeating summary indices, 431
incomplete blocks, non-parametric test of ordered alternatives, 1329
independence estimating equations (IEE), familial associations of lipid profiles, 3345
independent analysis, 861
Indianapolis-Ibadan Demential Project, 1645
individual agreement, total deviation index, 255
individual bioequivalence
  average bioequivalence connection, 2843
  bootstrap, 2741
  case studies, practical issues and observation, 2811
  criteria evaluation, 2775
  FDA draft guidance, 2879
  occasion-to-occasion vs mean switchability, 2797
  practical approach, 2721
  profile similarity, 2855
  regulatory considerations, 2821
  small sample confidence interval, 2885
  Special Issue, 2719
  subject-by-formulation interaction, 2867
  US draft guidance, 2769
individual difference ratio (IDR), 2821
information function, differential item functioning, 1651
initial level, Alzheimer's disease, 1441
instrumental activities of daily living (IADL), Alzheimer's disease, 1393, 1401
integrated weighted difference (IWD), interval censored data, 2611
intensive care unit patients, multi-state model, 3465
intention-to-treat
  non-compliance, 2689
  randomized clinical trials treatment effects, 1849
interaction effects, placebo-challenging designs, 1029
interim analyses
  see also group sequential trials
  sequential randomized trial, 3389
internal biostatistical consulting service, value estimation, 2131
internal pilot studies, sample size, 901
internal validity, Bradford Hill, 3149
International Society for Clinical Biostatistics (ISCB), 20th Annual Meeting
interpolation techniques, incidence prediction, 1741
interpretability, effect size measures, 1295
intersection-union principle, 2755
interval censored data
  hazard function, multiple imputation, 405
  HIV infection risk, 2641
  survival function, 2611
  two-sample test, 1
interval estimation, Cohen's kappa, 723
intraclass correlation, 2919
isodemographic maps, disease mapping, 2203
isotonic regression models, additive, 849
item characteristic curves
  differential item functioning, 1651
  global functioning measure, 1631

item response theory
  differential item functioning, 1651
  global functioning measure, 1631
iterated weighted least squares (IWLS)
  longitudinal data with truncated observations, 2975
  spatial disease rates, 2321

jack-knifing
  attributable risk confidence intervals, 1089
  Cohen's kappa interval estimation, 723
  cost-effectiveness analysis, 2989
  familial associations of lipid profiles, 3345
  generalized linear model predictive power, 1771
  risk factor assessment, 1523
  two-phase sampling, 1545
joinpoint regression, permutation tests, 335
joint maximum likelihood, differential item functioning, 1651
joint modelling, missing covariate values, 1237
Jonckheere test, non-parametric test of ordered alternatives, 1329
journals, statistical trends, 3275

Kaplan-Meier methods
  age at menopause genetic analysis, 1217
  censored biomarker measurements, 3171
  interval censored data, 2611
  leukaemia-free survival, 3005
  missing covariate values, 1237
  multiple comparisons, 353
  product-limit method, 1495
  prognostic survival models, 3401
  randomized clinical trials, 1039
  tumour staging and grading systems, 1997
kappa statistics, equality testing, 373
Kendall's tau
  Alzheimer's disease cognitive tests, 1411
  concordance, 3483
kernel smoothing, interval censored data, 2611
Kolmogorov-Smirnov confidence bands, ROC curves, 493
Kolmogorov-Smirnov test, interval censored data, 2611
Kullback-Leibler diagnostic, 221
Kullback-Leibler distance
  generalized linear model predictive power, 1771
  prognostic and diagnostic classification, 541
Kulldorf's scan test statistic, 191

L'Abbé plot, meta-analysis, 3251, 3497
Lan-DeMets method, group sequential longitudinal trials, 205
The Lancet, 3149
larynx cancer, disease mapping, 2493
last observation carried forward (LOCF), Alzheimer's disease, 1433
latent class analysis
  diagnostic testing, 1783
  risk factor assessment, 1523
latent class mixed model, biomarker trajectories, 1303
latent variable models, Alzheimer's disease, 1401
least absolute shrinkage and selection operator (Lasso), prognostic modelling, 1059
least squares estimation (LSE)
  Alzheimer's disease, 1421
  bioequivalence, 2775
  longitudinal studies with continuous outcomes, 1339
Lee, Wei and Amato (LWA) model, 13
leukaemia
  bootstrap confidence intervals, 1141
  cluster probability due to chance, 2195
  disease mapping, 2539
  multistate model, 3005
LG index, spatial model selection, 1915
licensing, pharmacovigilance, 3199
lifetime risk, Alzheimer's disease, 1495
likelihood function, generalized linear model predictive power, 1771
likelihood ratios
  censored biomarker measurements, 3171
  diagnostic tests comparison, 649
  patient-specific analysis, 83
  space-time models, 2569
linear Bayes models, disease mapping, 2217
linear discriminant models, unbalanced longitudinal data, 1969
linear mixed effects models
  spatio-temporal mortality patterns, 2251
  unbalanced longitudinal data, 1969
linear mixed model
  covariance structure modelling, 1793
  longitudinal Alzheimer's disease, 1617
  unbalanced longitudinal data, 1303
linear models
  acoustic rhinometry reproducibility, 1179
  longitudinal studies with continuous outcomes, 1339
  randomized clinical trials treatment effects, 1849
linear parametric models, continuous covariates modelling effect, 1831
linear random effects model, Alzheimer's disease, 1441
linear shrinkage factor, prognostic modelling, 1059
linked micromaps, 2521
lip cancer
  Bayesian disease mapping, 2579

disease mapping, 957
posterior predictive model checks, 2377
spatial model selection, 1915
liver cirrhosis, multi-state models, 587
LMS method, age-related trends, 697
local likelihood estimation, right censored data, 405
local linear regression, dose-response data, 389
log odds ratio
exact sequential tests, 3051
meta-analysis, 3251, 3417
sequential randomized trial, 3389
treatment comparison, 1115
log odds ratio regression, saddlepoint approximations, 323
log relative risk
generalized synthesis of evidence, 3359
proportional hazards model, 3309
log transformation, cubic smoothing spline models, 1191
log transformed data, symmetric percentage differences, 3109
log-likelihood
disease mapping, 2539
generalized linear model predictive power, 1771
log-linear models, 801
Bayesian accelerated failure time analysis, 221
malaria patients, 1931
matched case-control data, 35
spatio-temporal interaction, 2015
log-log survival plot, multiple comparisons, 353
log-normal model, cognitive tests reliability, 1411
log-normal survival models, Bayesian accelerated failure time analysis, 221
log-relative hazard, logrank test covariate imbalance, 1955
logarithmic scale, bioequivalence, 2769
logistic latent class model, 35
logistic models
attributable risk confidence intervals, 1089
prognostic factors with censored data, 601
logistic non-parametric model, continuation ratio random effects model, 3377
logistic regression
biomarker trajectories, 1303
birth weight, pregnancy risks, 239
cluster randomized trial, 2675
dose-response data, 389
missing covariate values, 1237
mixed models, messy longitudinal data, 2657
multiple imperfect assessments, 99
prognostic and diagnostic classification, 541
prognostic models, 141, 1059
randomized clinical trials treatment effects, 1849
saddlepoint approximations, 323
scoring systems, 575
two-phase sampling, 1545
logit models, treatment comparison, 1115
logrank statistics
cure rate models, 3023
multiple comparisons, 353
logrank test
covariate imbalance, 1955
interval censored data, 1
logspline density model, interval censored data, 2611
London School of Hygiene and Tropical Medicine, 3165
longitudinal biomarkers, disease onset, 617
longitudinal cross-cultural study, data management, 1645
longitudinal data, (Letter) 1821
Alzheimer's disease, 1401, 1433
with continuous outcomes, 1339
follow-up waves spacing, 1567
generalized linear models
goodness-of-fit, 1265
residuals analysis, 1277
linear discriminant models, 1969
mixed effects models, 1617
multiple regression modelling, 83
quality control measure, 1339
randomized clinical trials, 2657
sample size, 205
smoking and drinking interactions, 1685
transitional model, 71
with truncated observations, 2975
unbalanced, latent class mixed model, 1303
longitudinal rate of change, Alzheimer's disease, 1441
loss to follow-up, barrier methods, 71
Lou Gehrig's disease, incidence density, 1039
Louis' formula, proportional hazards model, 3309
lung cancer
messy longitudinal data, 2657
proportional hazards model, 3309
risk of smoking, 2185
space-time mixture modelling, 2333
space-time variation, 2555
spatio-temporal interaction, 2015
triple-goal estimates, 2295
within-area distribution of confounders, 45
lung disease, birthweight relationship, 937
Lyme disease, diagnostic tests comparison, 649
lymphoma, prognostic variable categorization, 113

malaria
log-linear models, 1931
meta-analysis bias, 3325
Mann-Whitney test, messy longitudinal data, 2657

Mantel-Haenszel estimators, treatment comparison, 1115
Mantel-Haenszel odds ratio, meta-analysis, 1707
marginal estimates, conditional models, 801
marginal maximum likelihood, differential item functioning, 1651
marginal models
  bivariate survival, 563
  cluster randomized trial, 2675
  generalized linear models goodness-of-fit, 1265
  paired organs, 525
  tumour response and survival, 837
marginal quasi-likelihood, meta-analysis, 3417
marginal survival functions, permutation tests, 2963
marker-based estimation, time since seroconversion estimation, 1753
Markov assumption, transitional models, 71
Markov chain Monte Carlo
  age at menopause genetic analysis, 1217
  age-specific incidence back-calculation, 281
  disease mapping, 2493, 2539
  fertility studies, 665
  foetal loss familial tendency, 2147
  HIV infected individuals estimation, 3095
  identifiability and convergence, 2279
  inference on a collapsed margin, 2243
  meta-analysis, 3497
  probabilistic small area risk assessment, 2345
  proportional hazards model, 3309
  reversible jump, 2361, 2579
  space-time models, 2569
  space-time variation, 2555
  spatial competing risk models, 2451
  spatial disease rates, 2321
  spatio-temporal interaction, 2015
  spatio-temporally misaligned data, 2265
  treatment comparison, 1115
Markov models
  leukaemia-free survival, 3005
  rheumatoid vasculitis, 3433
  tumour response and survival, 837
Markov process, AIDS incubation time uncertainty, 175
matched case-control data, direct modelling, 35
matched dichotomous data, sequential analysis, 3449
Mattis Dementia Rating Scale, 1651
MAX test, unbalanced factorial design clinical trials, 2079
maximized log-likelihood
  covariance structure modelling, 1793
  generalized linear model predictive power, 1771
maximum likelihood estimation (MLE)
  acoustic rhinometry reproducibility, 1179
  Alzheimer's disease, 1441
  approximate unconditional test of non-inferiority, 2089
  bioequivalence, 2769
  censored biomarker measurements, 3171
  change point model, 1555
  community-based studies, 1469
  comparative calibration, (Letter) 1253
  delayed onset disorders birth prevalence, 743
  differential item functioning, 1651
  disease mapping, 2203, 2493, 2539
  Gaussian repeated measures, 1101
  generalized Rudas-Clogg-Lindsay index of fit, 1881
  GLM goodness-of-fit, 1265
  interval estimation, 723
  longitudinal biomarkers, 617
  longitudinal data with truncated observations, 2975
  longitudinal studies with continuous outcomes, 1339
  meta-analysis, 3251
  multilevel model framework, 3417
  multiple imperfect assessments, 99
  multiple treatment courses, 1011
  prognostic modelling, 1059
  proportional hazards model, 3309
  risk factor assessment, 1523
  screening tests verification bias, 1697
  spatial disease rates, 2321
  stratified samples, 681
  treatment comparison, 1115
  triple-goal estimates, 2295
  two-phase sampling, 1545
  vaccine efficacy estimation, 827
maximum partial likelihood estimate (MPLE), prognostic factors sample size, 441
maximum plasma concentration, bioequivalence, 2855
mean integrated squared error (MISE), interval censored data, 2611
mean score imputation, dementia subtypes incidence estimation, 1577
mean squared difference, individual agreement, 255
mean squared error
  generalized linear model predictive power, 1771
  longitudinal data with truncated observations, 2975
  small area disease risks, 2409
mean switchability, individual bioequivalence, 2797
mean-homoscedastic model, unbalanced longitudinal data, 1969
measles, vaccine efficacy estimation, 827
measurement error
  diagnostic markers effectiveness, 2115
  ROC curves, 61
meiotic mapping techniques, 3337

meningiomas, GLM residuals analysis, 1277
menopause, genetic analysis, 1217
meta-analysis, (Letter) 753
  baseline risk, 3497
  bias, 3325
  generalised synthesis of evidence, 3359
  heterogeneity, 1707
  journal trends, 3275
  multilevel model framework, 3417
  odds ratio conversion, 3127
  pooling risk measures, 1901
  prognostic models, 141
  significance, 1707
  treatment effect and risk, 3251
Metropolis-Hastings algorithm, 281
  cluster modelling, 2361
  spatial competing risk models, 2451
Michigan Alzheimer's Disease Research Center, 1531
microarray technology, 3337
micromap plots, epidemiology, 2521
Min test, unbalanced factorial design clinical trials, 2079
Mini Mental State Examination (MMSE), 1393, 1411, 1463, 1469
  Alzheimer's disease, 1421, 1433, 1441, 1495
  changes modelling, 1607
  decline pattern modelling, 1593
  global functioning measure, 1631
  longitudinal Alzheimer's disease, 1617
Minimum Data Set Activities of Daily Living, 1593
minimum p-value approach, 113
minimum risk weights, stratified binomial trials, 811
misclassification adjustment, odds ratios estimation, 1523
missing data
  age at menopause genetic analysis, 1217
  Alzheimer's disease, 1433
  conditional models, 801
  continuation ratio random effects model, 3377
  dementia incidence, 1545
  dementia subtypes incidence estimation, 1577
  differential item functioning, 1651
  fertility studies, 665
  Gaussian repeated measures, 1101
  head and neck cancer, 1237
  logistic regression analysis, 99
  meta-analysis bias, 3325
  multiple imputation, 1
  non-parametric test of ordered alternatives, 1329
  screening tests verification bias, 1697
  two-phase surveys, 2101
mixed effects linear models
  bioequivalence, 2821
  individual bioequivalence, 2797, 2885
  robust procedures, 975
mixed effects models
  longitudinal Alzheimer's disease, 1617
  longitudinal biomarkers, 617
  spatio-temporal mortality patterns, 2251
mixed models
  age at menopause genetic analysis, 1217
  biomarker trajectories, 1303
  change point, 1555
  covariance structure modelling, 1793
  Gaussian repeated measures, 1101
  individual bioequivalence, 2721
  messy longitudinal data, 2657
mixed-scaling aggregate strategy, individual bioequivalence, 2879
mixture distribution modelling, patient-specific analysis, 83
mixture models
  disease mapping, 2217
  missing covariate values, 1237
model-based methods, disease mapping, 2203
model-robust quantal regression (MRQR), 389
modified profile likelihood, 323
moment method, bioequivalence, 2741, 2821, 2867
monotonic non-linear model, 2053
Monte Carlo
  additive isotonic regression models, 849
  Bayesian accelerated failure time analysis, 221
  bootstrap confidence intervals, 1141
  Cohen's kappa interval estimation, 723
  cost-effectiveness analysis, 2989
  diagnostic markers/repeated measurements comparison, 511
  dose-response data, 389
  effect size measures interpretability, 1295
  fertility studies, 665
  generalized linear model predictive power, 1771
  generalized population attributable fraction, 937
  interval censored data hazard function, 405
  joinpoint regression, 335
  kappa statistics equality testing, 373
  mixed effects models, 1617
  multiple comparisons, 353
  non-parametric test of ordered alternatives, 1329
  population bioequivalence, 2755
  risk ratio confidence intervals, 2933
  risk ratio homogeneity, 2919
  ROC curves regional confidence bands, 493
  spatial disease clustering, 191
  total deviation index, 255
  treatment comparison, 1115
  unbalanced factorial design clinical trials, 2079
Moran's I, Canadian Cancer Incidence Atlas, 2437

mortality data, HIV/AIDS epidemics reconstruction, 161
mortality ratios
see also standardized mortality/morbidity ratios (SMRs)
public health data analysis, 1081
MORVITA trial, recurrent event data, 13
moving average, profile similarity, 2855
multi-centre data, treatment comparison, 1115
multi-level logistic regression model, cluster randomized trial, 2675
multi-level models, 861
meta-analysis, 3417
multi-stage sampling, genetic epidemiology (Correction), 1251
multi-state models
intensive care unit patients, 3465
leukaemia-free survival, 3005
liver cirrhosis, 587
treatment effectiveness, 837
multi-state transitional models, unbalanced loss to follow-up, 71
multinomial logistic regression (MLR) model, vaccine protection, 3065
multinomial logit regression, loss to follow-up, 71
multinomial models, multiple treatment courses, 1011
multiple comparisons
carcinogenesis study, 353
sample size, 369
multiple imperfect assessments, logistic regression analysis, 99
multiple imputation
interval censored data hazard function, 405
two-sample test, 1
multiple linear regression
Alzheimer's disease cognitive change, 1421
patient-specific analysis, 83
multiple logistic regression, smoking and drinking interactions, 1685
Multiple Risk Factor Intervention Trial, 2689
multiple sclerosis, robust mixed linear model, 975
multiple testing adjustment, spatial disease clustering, 191
multiple treatment courses, evaluation, 1011
multiple-objective designs, optimal treatment allocation, 639
multiregion contact systems, STD epidemics, 2479
multivariate analysis, 861
multivariate analysis of variance, Gaussian repeated measures, 1101
multivariate models, blood pressure tracking, 2625
multivariate spatial models, event data, 2469
muscle biopsy specimens, vasculitis in rheumatoid arthritis, 3433
myelomatosis
continuous covariates modelling effect, 1831
monotonic non-linear model, 2053
myocardial infarction
pair-matched case-control study, 923
prognostic modelling, 1059

National Institute of Aging (NIA)
Alzheimer's Disease Data Coordinating Center, 1453
special care units, 1593, 1651
neck cancer, anaemia effects, 1237
negatively correlated binary responses, GEE analysis, 715
neoplasms, multivariate spatial models, 2469
nephroblastoma, approximate unconditional test of non-inferiority, 2089
nerve conduction velocity data, cubic smoothing spline models, 1191
network algorithm, dose-response studies, 3037
neural networks
journal trends, 3275
prognostic and diagnostic classification, 541
prognostic models, 453
neural tube defect, evidence-based medicine, 3291
Newton-Raphson algorithm
disease mapping, 2539
ecological studies, 45
prognostic and diagnostic classification, 541
prostate, 1303
spatial disease rates, 2321
time trends in adaptive designs, 2067
treatment comparison, 1115
Neyman-Pearson theory, 767, 785
non-compliance, randomized clinical trials treatment effects, 1849
non-Hodgkin's lymphoma, prognostic survival models, 3401
non-inferiority, approximate unconditional test, 2089
non-linear mixed effects model, unbalanced longitudinal data, 1969
non-linear models
incidence prediction (Correction), 1251
monotonic, 2053
randomized clinical trials treatment effects, 1849
non-linear parametric models, continuous covariates modelling effect, 1831
non-parametric Bayesian approach, HIV infection risk, 2641
non-parametric covariance methods, randomized clinical trials, 1039
non-parametric curve-fitting, continuous covariates modelling effect, 1831
non-parametric maximum likelihood estimator (NPMLE), 1

disease mapping, 2539
proportional hazards model, 3309
space-time mixture modelling, 2333
survival function, 2611
non-parametric maximum likelihood (NPML), triple-goal estimates, 2295
non-parametric methods
cost data analysis, 3219
disease mapping, 2203
non-parametric smoothing, disease mapping, 2217
non-parametric test of ordered alternatives, incomplete blocks, 1329
non-proportional hazards
interval censored data, 2611
multi-state model, 3465
prognostic survival models, 3401
non-randomized studies, journal trends, 3275
non-sigmoid curves, monotonic non-linear model, 2053
non-Studentized pivotal method, bootstrap confidence intervals, 1141
nosocomial infections, multi-state model, 3465
number needed to treat, 3275

Oberwolfach Conference on Medical Statistics, 421
observations, 2975
occasion-to-occasion switchability, individual bioequivalence, 2797
odds ratio
effect size conversion, 3127
meta-analysis, 1707
misclassification adjustment, 1523
r x k tables, 1901
randomized clinical trials treatment effects, 1849
optimal allocation ratio, 205
optimal treatment allocation, comparative biomedical studies, 639
oral candidiasis episodes, AIDS prognosis, 989
ordered alternatives, non-parametric test, 1329
ordered categorical data
concordance, 3483
directed vertex peeling, 2699
ordered logistic regression, scoring systems, 575
ordinal classification, scoring systems, 575
ordinal logistic regression, messy longitudinal data, 2657
ordinal responses, continuation ratio random effects model, 3377
ordinary least squares
Alzheimer's disease, 1441
covariance structure modelling, 1793
ordinary linear regression, GLM predictive power, 1771
ordinary logistic regression, cluster randomized trial, 2675
otitis media with effusion, effect size measures interpretability, 1295
ovarian cancer, prognostic factors sample size, 441
overparameterization, generalized linear model predictive power, 1771

Page test, non-parametric test of ordered alternatives, 1329
pain, concordance, 3483
pair-matched case-control study, sample size, 923
paired organs, diagnostic measurements, 525
parametric empirical Bayes estimation, stratified samples, 681
parametric models, continuous covariates modelling effect, 1831
parasuicide, cost data analysis, 3219
partial likelihood, recurrent event data, 13
partition structures, Bayesian methods, 2579
patient-specific analysis, sequential haematological data, 83
Pearson's chi-square statistic
age-specific reference intervals, 2943
incidence prediction, 1741
penalized log-likelihood, prognostic factors with censored data, 601
penalized maximum likelihood
prognostic modelling, 1059
prognostic models, 141
penalized quasi-likelihood (PQL)
conditional autoregressive models, 2421
disease mapping, 957
multilevel model framework, 3417
random effects models, 1265
spatial disease rates, 2321
percentile methods
bootstrap, 1141, 2741
cost data analysis, 3219
permutation bands, age-specific reference intervals, 2943
permutation tests
clinical trials, 1319
cost data analysis, 3219
joinpoint regression, 335
marginal survival functions, 2963
randomized clinical trials treatment effects, 1849
Peto-Prentice statistic, 353
pharmaceutical industry regulation, 3199
pharmacovigilance, 3199
Physical and Self Maintenance Scale (PSMS), 1401
piecewise exponential models, intensive care unit patients, 3465
Pillai-Bartlett trace test, 1101

pilot studies, sample size, 901
placebo-challenging designs, clinical trials, 1029
placebo-treatment comparison, 639
play-the-winner-and-drop-the-loser algorithms, 1011
plots, prognostic variable categorization, 113
point data, disease mapping, 2203
Poisson distribution, incidence prediction, 1741
Poisson likelihood, seasonal SEIR models, 1207
Poisson regression model
  disease mapping, 2377
  ecological studies, 45
Poisson variation, joinpoint regression, 335
Poisson-gamma model
  disease mapping, 2539
  spatial model selection, 1915
Poisson-log-Gaussian model, disease mapping, 2377
Poisson-normal mixed effects models, spatio-temporal mortality patterns, 2251
polychotomous logistic regression, biomarker trajectories, 1303
polynomial models, Alzheimer's disease, 1401
polynomial parametric models, continuous covariates modelling effect, 1831
polytomous item response theory, differential item functioning, 1651
pool adjacent violators (PAV) algorithm, 849
population attributable fraction, generalized, 937
population bioequivalence, 2719, 2721, 2741, 2755, 2769, 2811, 2821, 2885
post-operative pain, antedependence test, 1889
posterior computations, accelerated failure time analysis, 221
posterior predictive model checks, disease mapping, 2377
power, 2089
  age-specific reference intervals, 2943
  censored biomarker measurements, 3171
  clustering, 1363
  contrast-based test, 913
  cubic smoothing spline, 1831
  dose-response studies, 3037
  individual bioequivalence, 2741
  internal pilot studies, 901
  optimal treatment allocation, 639
  permutation tests, 2963
  population bioequivalence, 2755
power-exponential curves, continuous covariates modelling effect, 1831
power-exponential model, monotonic non-linear model, 2053
PQL *see* penalized quasi-likelihood
Practical Incidence Estimators macro, Alzheimer's disease, 1495
predictive power, group sequential designs, 3023
predictive quasi-likelihood method, cluster randomized trial, 2675
predictive variability penalty (PEN), space-time models, 2569
pregn..ncy
  linear discriminant models, 1969
  malaria, 3325
  meta-analysis, 3417
  smoking risks, 239
Prentice, Williams and Peterson gap time model (PWP-GT), 13
Prentice, Williams and Peterson total time model (PWP-CP), 13
pressure sores prevention, sequential randomized trial, 3389
prevalence
  Alzheimer's disease, 1481
  community-based studies, 1469
prevalence-free utility-respecting summary indices, 431
prevalent cohort study, decline pattern modelling, 1593
preventive clinical trials, cancer, 1983
primary biliary cirrhosis, continuous covariates modelling effect, 1831
probability density function, multi-state model, 3465
probability models, multiple treatment courses, 1011
probability values, journal trends, 3275
probit mixture models, fertility studies, 665
profile likelihood, change point model, 1555
profile similarity, bioequivalence, 2855
profiles, 3345
prognosis, 324
  AIDS, 989
  meaning, 425
prognostic classification, 271
  artificial neural networks, 541
prognostic factors
  censored data, 601
  sample size, 441
prognostic index, logrank test covariate imbalance, 1955
prognostic models, 425
  logistic regression analysis, 141, 1059
  validation, 453
prognostic survival models, 3401
prognostic variable categorization, 113
projection methods, disease mapping, 2203
proportional hazards
  age at menopause genetic analysis, 1217
  Alzheimer's disease, 1495
  cause-specific, 3065
  interval censored data, 1, 2611
  prognostic factors with censored data, 601

with random effects, 3309
randomized clinical trials, 1039
treatment effects, 1849
proportional reduction in deviance measure, 1265
proportional reduction in entropy measure, 1265
proportional reporting ratios, 3199
proportional-odds regression, scoring systems, 575
proportionality constant, Alzheimer's disease, 1481
prospective alpha allocation scheme (PAAS), 763, 767, 781, 785, 795
prostate cancer
cumulative cause-specific mortality, 1729
inference on a collapsed margin, 2243
latent class mixed model, 1303
longitudinal biomarkers, 617
multiple treatment courses, 1011
pseudo-likelihood estimation, risk factor assessment, 1523
pseudo-maximum likelihood
community-based studies, 1469
two-phase sampling, 1545
public health data
space-time mixture modelling, 2333
standardized mortality ratios, 1081

Q-tests, age-specific reference intervals, 2943
quality control measure, longitudinal studies, 1339
quality of life
messy longitudinal data, 2657
random effect selection model, 3237
quantile regression, age-specific reference intervals, 2943
quantitative diagnostic test, bootstrap confidence intervals, 313
quasi-likelihood, Gaussian repeated measures, 1101
quasi-Newton algorithm, seasonal SEIR models, 1207

R^2, effect size measures interpretability, 1295
random coefficients, 861
random effects, 861
Alzheimer's disease, 1401, 1421
blood pressure tracking, 2625
cluster summary statistics, cluster randomized trial, 2675
community-based studies, 1469
continuation ratio, 3377
covariance structure modelling, 1793
decline pattern modelling, 1593
generalized linear models goodness-of-fit, 1265
longitudinal Alzheimer's disease, 1617
meta-analysis, 1707, 3359
proportional hazards model, 3309
rheumatoid vasculitis, 3433
selection model, quality of life, 3237
space-time mixture modelling, 2333
treatment comparison, 1115
random growth curve models, 861
randomized controlled trials, journal trends, 3275
randomized trials
cost data analysis, 3219
logrank test covariate imbalance, 1955
longitudinal data, 2657
multi-level model, 2675
non-compliance, 2689
non-parametric covariance methods, 1039
permutation tests, 1319
practical issues, 3389
treatment effects, 1849
rank-transferrable pattern of agreement (RTPA), 3483
Rao's F approximation, Gaussian repeated measures, 1101
Rasch model, matched case-control data, 35
rate of change, Alzheimer's disease, 1441
rater agreement, generalized Rudas-Clogg-Lindsay index of fit, 1881
ratings using different scales, concordance, 3483
ratio estimation, angular transformation, 2989
realistic-age-structured (RAS) models, 1207
realized probability of dying (RPD), 1729
receiver operating characteristic (ROC) curves, 431
see also area under ROC curve
diagnostic markers effectiveness, 2115
diagnostic markers/repeated measurements comparison, 511
diagnostic tests comparison, 649
longitudinal biomarkers, 617
random measurement error, 61
regional confidence bands, 493
screening tests verification bias, 1697
reciprocals of variances of stratum-specific differences (INVAR), 811
rectal cancer, sequential analysis, 3449
recurrent event data, survival analysis, 13
recursive partitioning
stability, 475
survival data, 601
reference-scaled method, bioequivalence, 2821, 2885
regenerative semi-Markov process, cancer prevention trials design, 1983
regression models
Alzheimer's disease, 1401
ecological studies, 45
regression trees, prognostic models, 453
regression-smoothed estimator, stratified samples, 681

regressive logistic probability models, multiple treatment courses, 1011
regret graphs, diagnostic tests comparison, 649
regulatory process, pharmacovigilance, 3199
relative numerical error, generalized population attributable fraction, 937
relative risk
  disease mapping, 2203, 2493
  ecological studies, 45
relative survival, cumulative cause-specific mortality, 1729
relevance weighted likelihood (REWL), time trends in adaptive designs, 2067
reliability
  Alzheimer's disease cognitive tests, 1411
  incidence prediction, 1741
reliability theory, generalized treatment effects, 887
REML *see* restricted maximum likelihood
Renyi-type statistics, marginal survival functions, 2963
repeatability, acoustic rhinometry reproducibility, 1179
repeated confidence intervals, group sequential designs, 3023
repeated measures
  Alzheimer's disease, 1421
  analysis of variance, post-operative pain, 1889
  covariance structure modelling, 1793
  diagnostic markers comparison, 511
  longitudinal data analysis, (Letter) 1821
  longitudinal data with truncated observations, 2975
  missing data, 1101
  summary statistics, (Letter) 3133
  Tutorial in Biostatistics, 861
repeated ordinal responses, continuation ratio random effects model, 3377
repeated screening events, cumulative risk, 1865
reproducibility
  acoustic rhinometry, 1179
  six-minute walking test, 3087
residuals analysis, generalized linear models, 1277
respiratory tract infection, meta-analysis, 3417
responses, 715
restricted iterative generalized least squares (RIGLS), 3237
restricted maximum likelihood (REML)
  bioequivalence, 2775
  cluster randomized trial, 2675
  covariance structure modelling, 1793
  Gaussian repeated measures, 1101
  individual bioequivalence, 2721, 2741, 2867
  meta-analysis, 3417
  six-minute walking test reproducibility, 3087
retrospective estimation, delayed onset disorders birth prevalence, 743
reversible jump Markov chain Monte Carlo (RJMCMC), 2361, 2579
rheumatoid arthritis, muscle biopsy specimens, 3433
right censored data
  local likelihood estimation, 405
  multiple comparisons, 353
risk
  absolute risk reduction, 3275
  attributable risk, 1089
  baseline risk, 2689, 3497
  competing risks failure time methods, 3065
  cumulative, 1865
  lifetime risk, 1495
  log relative risk, 3309, 3359
  meta-analysis, 3251, 3497
  minimum risk weights, 811
  multi-state model, 3465
  relative risk, 45, 2203, 2493
risk assessment, 2345
risk difference
  meta-analysis, 1707
  non-compliance and sample size, 2689
  r x k tables, 1901
risk factors
  assessment, odds ratios estimation, 1523
  log-linear models, 1931
  pair-matched case-control study, 923
risk intervals, Cox-based recurrent event model, 13
risk models, sliding time windows, 2185
risk ratio
  confidence intervals, 2933
  homogeneity, 2919
  r x k tables, 1901
risk set, Cox-based recurrent event model, 13
RJMCMC *see* reversible jump Markov chain Monte Carlo
Robbins-Monro algorithm, bootstrap confidence intervals, 1141
robust mixed linear model, longitudinal data, 975
robust variance, recurrent event data, 13
ROC curves *see* receiver operating characteristic (ROC) curves
Rosner model, 525
roughness penalty approach, continuous covariates modelling effect, 1831
Rubin causal model, 937
Rudas-Clogg-Lindsay index of fit, rater agreement, 1881
Runge-Kutta method, seasonal SEIR models, 1207

S-distributions, age-related trends, 697

saddlepoint approximations, small sample logistic regression, 323
safety monitoring, life-threatening conditions, 2899
sample size
  bioequivalence, 2769
  cancer prevention trials design, 1983
  censored biomarker measurements, 3171
  community-based studies, 1469
  compliance information, 2689
  disaggregate criterion, 2755
  disease mapping, 957
  dose-response studies, 3037
  exact sequential tests, 3051
  generalized Rudas-Clogg-Lindsay index of fit, 1881
  group sequential longitudinal trials, 205
  individual bioequivalence, 2741
  inflation factor, 205
  internal pilot studies, 901
  multiple comparisons, 369
  multiple treatment courses, 1011
  pair-matched case-control study, 923
  prognostic factors, 441
  prospective alpha allocation scheme, 767
  ROC curves regional confidence bands, 493
  sequential analysis, 3449
  small
    Gaussian repeated measures, 1101
    multiple comparisons, 353
    prognostic modelling, 1059
    saddlepoint approximations, 323
  unbalanced factorial design clinical trials, 2079
sampling, community-based studies, 1469
Scale-up and Post-approval Changes (SUPAC) guidance, 2719
Schwarz criterion, spatial model selection, 1915
Schwarz's Bayesian criterion, covariance structure modelling, 1793
scoring systems, ordinal classification, 575
screening
  breast cancer, 3359
  false-positive cumulative risk, 1865
  verification bias, 1697
seasonal SEIR models, contact rate estimation, 1207
secondary endpoints, alpha control, 763, 767, 781, 785, 795
secondary variables, prospective alpha allocation scheme, 763
SEER*STAT Survival System, 1729
segmented mixed effect models, longitudinal biomarkers, 617
self-harm, cost data analysis, 3219
semi-Markov models
  leukaemia-free survival, 3005
  multi-state models, 587, 3465
  tumour response and survival, 837
semiparametric approach, dose-response data, 389
sensitivity
  bootstrap confidence intervals, 313
  diagnostic testing, 1783
sensitivity analysis
  accelerated failure time analysis, 221
  generalised synthesis of evidence, 3359
  GLM residuals analysis, 1277
  meta-analysis, 3251, 3325
sequential analysis, matched dichotomous data, 3449
sequential conditional probability ratio test, 205
sequential designs, time trends, 2067
sequential haematological data, patient-specific analysis, 83
sequential probability ratio test, 3449
sequential randomized trial, practical issues, 3389
sequential saddlepoint approximation, 323
sequential safety procedure, life-threatening conditions, 2899
seroprevalence, time since seroconversion estimation, 1753
sexually transmitted diseases epidemics, multiregion contact systems, 2479
Shannon entropy, 431
shrinkage
  dementia subtypes incidence, 1577
  prognostic models, 141, 1059
sieve analysis, vaccine protection, 3065
significance, meta-analysis, 1707
simulation
  see also Markov chain Monte Carlo
  approximate Bayesian bootstrap (ABB), 1
  attributable risk confidence intervals, 1089
  bootstrap confidence intervals, 313, 1141
  Canadian Cancer Incidence Atlas, 2437
  censored biomarker measurements, 3171
  confidence interval approach, 2885
  cubic smoothing spline, 1831
  diagnostic markers effectiveness, 2115
  disease mapping, 957, 2217, 2493
  ecological studies, 45
  familial associations of lipid profiles, 3345
  Gaussian repeated measures, 1101
  generalized treatment effects, 887
  headbanging algorithm, 2309
  incidence prediction, 1741
  individual bioequivalence, 2741, 2775, 2797, 2867
  inference on a collapsed margin, 2243
  interval censored data survival function, 2611
  joinpoint regression, 335
  longitudinal data with truncated observations, 2975
  longitudinal studies with continuous outcomes, 1339

Monte Carlo
Cohen's kappa interval estimation, 723
cost-effectiveness analysis, 2989
diagnostic markers/repeated measurements comparison, 511
dose-response data, 389
effect size measures interpretability, 1295
fertility studies, 665
generalized linear model predictive power, 1771
interval censored data hazard function, 405
kappa statistics equality testing, 373
mixed effects models, 1617
non-parametric test of ordered alternatives, 1329
population bioequivalence, 2755
risk ratio confidence intervals, 2933
risk ratio homogeneity, 2919
ROC curves regional confidence bands, 493
spatial disease clustering, 191
total deviation index, 255
unbalanced factorial design clinical trials, 2079
multiple treatment courses, 1011
patient-specific analysis, 83
permutation tests, 2963
post-operative pain, 1889
randomized clinical trials treatment effects, 1849
recurrent event data, 13
ROC curves, 61
saddlepoint approximations, 323
sequential analysis, 3449
sliding time windows, 2185
spatial competing risk models, 2451
spatial model selection, 1915
standardized mortality ratios, 1081
stratified binomial trials, 811
stratified samples from community populations, 681
time to onset of response, 2169
triple-goal estimates, 2295
two-phase surveys, 2101
vaccine efficacy estimation, 827
vaccine protection, 3065
simultaneous autoregressive (SAR) models, 957
single nucleotide polymorphism (SNP), 3337
six-minute walking test reproducibility, 3087
sleep apnoea, r x k tables, 1901
sliding time windows, temporal effects exploratory analysis, 2185
sliding-window approach, STEPP, 2595
small cell lung cancer, longitudinal data, 2657
smoking
Alzheimer's disease, 1685
dementia study, 1523
lung cancer risk, 2185
pregnancy risks, 239
smoothing
age-specific incidence back-calculation, 281
age-specific reference intervals, 2943
bioequivalence, 2855
community-based studies, 1469
cubic smoothing spline models, 1191
disease mapping, 957, 2203, 2493
headbanging algorithm, 2309
HIV & AIDS surveillance data, 297
interval censored data, 2611
space-time models, 2569
spatial disease rates, 2321
spatial filters, 2399
smoothing by roughening (SBR), triple-goal estimates, 2295
smoothing parameter, prognostic factors with censored data, 601
smoothing weights, HIV incidence rates estimation, 1165
Somer's delta, 1901, 3483
space-time mixture modelling, public health data, 2333
space-time models
environmental pollution, 2569
spatial competing risk models, 2451
space-time SIS model, multiregion contact systems, 2479
space-time variation, Bayesian modelling, 2555
spatial competing risk models, disease mapping, 2451
spatial disease clustering, multiple testing adjustment, 191
spatial filters, smoothed maps, 2399
spatial models
Markov chain Monte Carlo, 2279
selection, indices comparison, 1915
spatial smoothing, headbanging algorithm, 2309
spatial-birth-death-shifting (SBDS) algorithm, 2361
spatio-temporal interaction, disease mapping, 2015
spatio-temporal mortality patterns, mixed effects models, 2251
spatio-temporally misaligned data, hierarchical models, 2265
Special Issues
20th Meeting of ISCB, 3307
Alzheimer's Disease Research, 1389
Current Perspectives and Future Directions in Medical Statistics, 3147
Disease Mapping, 2201
Individual Bioequivalence, 2719
Oberwolfach Conference on Medical Statistics, 421
specificity, diagnostic testing, 1783
spending functions, exact sequential tests, 3051

spline, cubic smoothing, 1191, 1831
split-plot analysis, 861
split-plot design, post-operative pain, 1889
standard errors
  community-based studies, 1469
  covariance structure modelling, 1793
  negatively correlated binary responses, 715
standardized area under the curve, messy longitudinal data, 2657
standardized incidence ratio (SIR), Canadian Cancer Incidence Atlas, 2437
standardized mortality/morbidity ratios (SMRs)
  Bayesian disease mapping, 2579
  disease mapping, 2493, 2539
  public health data analysis, 1081
  small area disease risks, 2409
standardized rate ratios (SRRs), public health data analysis, 1081
Steel's test, multiple comparisons, 353
stepwise selection
  prognostic modelling, 1059
  prognostic models, 453
stereotype logistic regression, scoring systems, 575
stochastic models
  cancer prevention trials design, 1983
  smoking during pregnancy, 239
stopping boundary, sequential randomized trial, 3389
stopping rules
  group sequential designs, 3023
  safety monitoring, 2899
  sequential analysis, 3449
stratified binomial trials, minimum risk weights, 811
stratified designs, community-based studies, 1469
stratified logrank test, covariate imbalance, 1955
stratified random sampling, logrank test covariate imbalance, 1955
stratified samples, parametric empirical Bayes estimation, 681
stratum-specific sample sizes (SSIZE), 811
strokes
  cocaine, 99
  safety monitoring, 2899
studentized pivotal method, bootstrap confidence intervals, 1141
studentized test-inversion bootstrap, confidence intervals, 1141
subgroup analysis, meta-analysis bias, 3325
subject-by-formulation interaction, 2821
  estimated variance component, 2867
subpopulation treatment effect pattern plot (STEPP), 2595
sum of squared error, Monte Carlo, 389
summary measures
  bioequivalence, 2855
  cluster randomized trial, 2675
  diagnostic power, 431
  generalized linear model predictive power, 1771
  longitudinal studies, 1617
  messy longitudinal data, 2657
  meta-analysis, 3417
  post-operative pain, 1889
  repeated measures, 861
summary score approach, Alzheimer's disease, 1433
superpopulation
  community-based studies, 1469
  generalized population attributable fraction, 937
sure outcomes of random events (SORE), 239
Surveillance, Epidemiology and End Results (SEER) Program, 1729
survival analysis
  Bayesian accelerated failure time analysis, 221
  bootstrap confidence intervals, 1141
  conditional models in bivariate survival, 563
  cumulative cause-specific mortality, 1729
  interval censored data, 1, 2611
  leukaemia-free survival, 3005
  missing covariate values, 1237
  multi-state models, 587
  multiple comparisons, 353
  prognostic, 3401
  prognostic and diagnostic classification, 541
  prognostic factors with censored data, 601
  prognostic factors sample size, 441
  proportional hazards model, 3309
  random effect selection model, 3237
  randomized clinical trials treatment effects, 1849
  recurrent event data, 13
  spatial competing risk models, 2451
  time since seroconversion estimation, 1753
  tumour response and survival, 837
  tumour staging and grading systems, 1997
survival curves, accelerated failure time analysis, 221
susceptible-infective-susceptible (SIS) model, multi-region contact systems, 2479
susceptibles-exposed-infectives-recovered (SEIR) model, 1207
switchability, 2797, 2821, 2879, 2885
symmetric polychotomous logistic regression model, 525
sympercents, 3109

tail-oriented pattern plot, 2595
Tango's general test, clustering, 1363

Taylor series approximation, cluster randomized trial, 2675
temporal effects exploratory analysis, sliding time windows, 2185
test characteristic curves, global functioning measure, 1631
test-inversion bootstrap, confidence intervals, 1141
three-state transitional model, loss to follow-up, 71
thymoma, tumour staging and grading systems, 1997
time trends, adaptive designs, 2067
time-by-time method, post-operative pain, 1889
time-dependent effects, exposure histories, 2185
time-independent methods, vaccine protection, 3065
time-to-event data, non-parametric covariance methods, 1039
time-to-maximum concentration, bioequivalence, 2855
time-to-onset of response, antidepressant clinical trials, 2169
Toeplitz covariance, 2657
Toeplitz structure, covariance structure modelling, 1793
total deviation index, individual agreement, 255
total time - restricted (TT-R) model, 13
total time model, 13
transitional model, barrier methods, 71
tree stability diagnostics, 475
tree-based models, prognostic factors with censored data, 601
tree-based predictors, 475
trend tests, power comparisons, 3037
triangular design, sequential randomized trial, 3389
triangular test
  discrete responses, 3051
  matched data, 3449
trilinear models
  Alzheimer's disease, 1401
  decline pattern modelling, 1593
triple-goal estimates, disease mapping, 2295
trivariate normal model, colorectal hepatic metastases, 3237
truncated observations, longitudinal data, 2975
truncation models, Alzheimer's disease cognitive tests, 1411
Turnbull's cluster evaluation permutation procedure, 1363
Turner's syndrome, exact sequential tests, 3051
Tutorial in Biostatistics
  covariance structure modelling, 1793
  longitudinal data analysis, (Letter) 1821
  meta-analysis, (Letter) 753
  prognostic variable categorization, 113
  repeated measures, 861
  treatment comparison, multi-centre data, 1115
TWiST, Hepatic Artery Pump trial, 3237
two one-sided tests procedure (TOST), bioequivalence, 2843
two-contrast tests, dose response, 913
two-phase sampling, dementia incidence, 1545
two-phase surveys, disease prevalence estimation, 2101
two-sample *t* test
  cost data analysis, 3219
  population bioequivalence, 2755
two-sample test, interval censored data, 1
two-stage designs, screening tests, 1697
type I error
  antedependence test, 1889
  cubic smoothing spline, 1831
  Gaussian repeated measures, 1101
  internal pilot studies, 901
  non-inferiority, 2089
  prospective alpha allocation scheme, 763, 767
  sequential analysis, 3449
  spending functions, group sequential longitudinal trials, 205
  trend tests, 3037
  unbalanced factorial design clinical trials, 2079
type II error, sequential analysis, 3449

UC Davis Alzheimer's Disease Center, 1631
unbalanced longitudinal data, linear discriminant models, 1969
unbiased weighted least-squares (UWLS), longitudinal data with truncated
unconditional exact test, non-inferiority, 2089
unconditional test, non-inferiority, 2089
University of Western Ontario Dementia Study, 1685
urn models, vaccine efficacy estimation, 827

vaccine efficacy
  approximate unconditional test of non-inferiority, 2089
  urn models, 827
vaccine protection, strain variations, 3065
validity
  Bradford Hill, 3149
  common sense and figures, 3149
  multi-state model, 3465
  permutation tests, 1319
  prognostic models, 453
  prognostic survival models, 3401
  standardized mortality ratios, 1081

variance
  Alzheimer's disease cognitive tests, 1411
  effect size measures interpretability, 1295
variance inflation factor, prognostic factors sample size, 441
variance stabilized bootstrap-*t*, cost data analysis, 3219
variance-homoscedastic model, unbalanced longitudinal data, 1969
vasculitis in rheumatoid arthritis, muscle biopsy specimens, 3433
verification bias, screening tests, 1697
veterinary epidemiology, Bayesian accelerated failure time analysis, 221
viral load measurements, HIV, 3171
visual analogue scale
  concordance, 3483
  post-operative pain, 1889
vitamin A supplementation, randomized clinical trials treatment effects, 1849

Wald test
  censored biomarker measurements, 3171
  cluster randomized trial, 2675
  familial associations of lipid profiles, 3345
  meta-analysis, 3417
  prognostic factors sample size, 441
Wald-Wolfowitz run test, GLM residuals analysis, 1277
Wei, Lin and Weissfeld (WLW) model, 13
Weibull models
  age at menopause genetic analysis, 1217
  bivariate survival, 563
  prognostic survival model, 3401
weighted generalized least squares, community-based studies, 1469
weighted Kaplan-Meier (WKM), 1
weighted least squares, 2919
  differential item functioning, 1651
  dose-response data, 389
  incidence density, 1039
  meta-analysis, 3251, 3497
weighted logistic regression, two-phase sampling, 1545
weighted mean squared error, small area disease risks, 2409
weighting strategies, 811
weighting type estimator, two-phase surveys, 2101
Wilcox-Russell model, 239
Wilcoxon test
  censored biomarker measurements, 3171
  interval censored data, 1
  non-parametric test of ordered alternatives, 1329
Wilcoxon-Mann-Whitney test, ordered categorical data, 2699
Wilks' test, Gaussian repeated measures, 1101
within-area distribution of confounders, 45
within-subjects correlation, Cox-based recurrent event model, 13
within-subjects variability, robust mixed linear model, 975

Yerushalmy's paradox, 239
Youden's index, 431, 649

Z-scores, age-specific reference intervals, 2943